IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP - CPP-1X (Eflornithine HCl)/Sulindac 
CPP FAP-310 Ver 5.2, 17January2019 Cover Page  
 
A DOUBLE-BLIND, RANDOMIZED , PHASE III TRIAL OF THE 
SAFETY AND EFFICACY OF CPP-1X / SULINDAC 
COMPARED WITH CPP-1X, SULINDAC AS SINGLE AGENTS 
IN PATIENTS WITH FAMILIA L ADENOMATOUS POLYPOSIS 
(FAP) 
CPP FAP-310 
CPP-1X (Eflornithine HCl) 
 
EudraCT Number: 2012-000427-41xE 
NCT Number: 01483144 
 
Date: 17January2019 
Version: 5.[ADDRESS_1102560] 
Tucson, AZ [ZIP_CODE] 
 
 
Confidentiality Statement 
The information contained herei n is the proprie tary property of  Cancer Prevention 
Pharmaceuticals, Inc. and any una uthorized disclosure of such i nformation without prior written 
authorization of Cancer Preventi on Pharmaceuticals, Inc. is exp ressly prohibited. 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  1 TABLE OF CONTENTS 
1. GENERAL INFORMATION ........................................... ...................................................6  
 Protocol Title ................................................ .....................................................................6  
 Sponsor and Study Monitor ...............................................................................................6  
 Other Medical and/or T echnical Departments ..................................................................7  
 Signature [CONTACT_799425] ...... .....................................7  
 Clinical Investigators and Study Leadership .....................................................................7  
 Study Schema .................................................. ..................................................................9  
2. BACKGROUND INFORMATION ........................................ ..........................................10  
 Natural History, Current Surgical and Endoscopic Treatment .... ....................................10  
 Pharmacologic Clinical Trials in FAP Patients ................. ..............................................10  
 Sulindac Alone ................................................ ..........................................................11  
 Celecoxib Alone ............................................... .........................................................11  
 NSAIDs Plus Eflornithine Combination .......................... .........................................12  
 Eflornithine Alone ............................................ ........................................................12  
 Sulindac and Eflornithine; Colorectal Polyp Chemoprevention ... ..................................13  
 Biology Of Eflornithine ...................................................................................................13  
 Rationale for Eflornithine Dose .......................................................................................14  
 Rationale for Sulindac Dose ................................... .........................................................15  
 Summary of Known and Potential Risks .......................... ...............................................16  
 Cardiac Risk .................................................. ............................................................16  
 Ototoxicity Risk .............................................. ..........................................................16  
 Sulindac Black Box Warning ....................................................................................17  
3. TRIAL OBJECTIVES AND PURPOSE .................................. .........................................17  
 Rationale .................................................................................................................... ......17  
 Rationale for Treatment Durati on Extension up to 48 Months .......................................19  
 Purpose ....................................................... ............................................................... ......21  
4. INVESTIGATIONAL PLAN ............................................................................................22  
 Study Population ............................................................................................................. 22 
 Treatment ..................................................... ............................................................... .....22  
 Randomization ................................................. ............................................................... .23 
 Primary Outcome .............................................................................................................2 3 
 Secondary Outcomes ............................................ ...........................................................23  
 Population Pharmacokinetic s for CPP-1X/Sulindac .......................................................24  
 Polyamine Analysis ............................................ .............................................................24  
 Pharmacogenetic and Genetic Analysis .......................... ................................................24  
 Quality of Life ............................................... ............................................................... ...25  
5. STUDY DRUG INFORMATION ........................................ .............................................26  
 CPP-1X [Eflornithine HCl] ..................................... ........................................................26  
 Eflornithine Clinic al Pharmacology .........................................................................26  
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  2 
 CPP-1X (Eflornithine) Pharmacokinetics ........................ .........................................[ADDRESS_1102561] Assessments and Treatment Schedule ................................................................34  
 Patient Accrual Logistics .................................................................................................38  
 Initial Visit – Determini ng Potential Eligibility.............. ..........................................38  
 Subsequent Screening for Eligibility ........................................................................38  
 Final Eligibility and Potential Screen Failures ............... ..........................................38  
 Drug Administration ........................................... ......................................................39  
 Initial 24-Month Treatment Intervention Assessments .............................................39  
 Initial 24 Month Treatment Intervention Early Termination (+ 2 weeks) ................40  
 Initial 24 Month Treatment Inte rvention Follow-Up (30-days post  end of treatment 
visit +/- 1 week) Off Study ................................... ....................................................41  
 Initial 24 Month Treatment Intervention Follow-Up (Months 2-6, each month +/- 1 
week) Off Study ............................................... .........................................................41  
 Treatment Extension Intervention (Months 25 - 48) ............. ...................................42  
 Treatment Extension - End of Treatment/Early Termination (+/- 2  weeks) .............43  
 Treatment Extension Follow-Up (30- days post end of treatment vi sit +/- 1 week) Off 
Study ......................................................... ............................................................... .43 
 Termination of Treatment Extension Procedures ................. ....................................43  
 Treatment Compliance .......................................... ....................................................44  
 Definition of FAP-Related Event s or Serious and Unexpected Toxicity .................44  
 Study Blinding Information and Cr iteria for Protocol Treatment Removal ....................45  
 Blinding and Unblinding........................................ ...................................................45  
 Protocol Treatment Withdra wal (Off-Study Treatment) ..........................................46  
 Protocol Withdrawal (Off-Study) ............................... ..............................................46  
9. DISEASE ASSESSMENT AND SAMPLE COLLECTION ............................................46  
 Baseline Endoscopy ............................................ .............................................................46  
 Follow-up Endoscopi[INVESTIGATOR_014] ......................................... ..........................................................47  
 Imaging Submission ............................................ ............................................................47  
 Population Pharmacokinetic Sampling ........................... .................................................48  
 Polyamine Sample Collection (Nor mal Mucosa Biopsy, Random Urine Sample) .........49  
 Pharmacogenomic and Genetic T esting Sample Collection ......... ..................................49 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102562] Rates .................................................. ...........................................................59  
 Populations for Analysis ..................................................................................................60  
 Intent-to-Treat (ITT) Population ...............................................................................60  
 Safety Population ......................................................................................................60  
 Per Protocol Population ............................................................................................61  
 Other Populations.............................................. ........................................................61  
 Other Statistical Methods ..................................... ...........................................................61  
 Demographic and Baseline Characteristics ...................... ........................................61  
 Patient Disposition and Treatment Summaries ................... ......................................61  
 Categorical or Continuous-Valued Secondary Outcome and Safety D ata ...............62  
 Subgroup Analyses ............................................. ......................................................62  
 Health Related Quality of Life (HRQoL) ........................ .........................................[ADDRESS_1102563] .............................. .....................................................66  
 Investigator Documentation .................................... ........................................................66  
 Protocol Amendments ........................................... ..........................................................67  
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102564] .............................................................................................................. .69 
 Informed Consent ............................................................................................................6 9 
 Confidentiality ............................................... ............................................................... ...69  
15. LISTING OF ABBREVIATIONS ...................................... ...............................................70  
16. REFERENCES .................................................... ..............................................................7 2 
 
APPENDIX A  SPI[INVESTIGATOR_799285]’S SCORE AND STAGE ..........................................................78  
APPENDIX B  INSIGHT RECTUM/POUCH ASSESSMENT AND STAGE95 .....................[ADDRESS_1102565] OF TABLES 
Table 1 - Composition of CPP-1X ( Eflornithine HCl), 250 mg Tablets ........................................ 26  
Table 2 - Composition of S ulindac 150 mg Tablets .............. ......................................................... 28  
Table 3 - FAP Study Schedule (Ini tial 24 Months of Treatment) . .................................................. 34  
Table 4 - FAP Study Schedule (Tre atment Extension to a Maximum of 48 Months) .................... 36  
Table 5 - Study Medication Schedule1 ............................................................................................ 39  
Table 6 – Pharmacokinetic Sample  Number, Sampling Times and EKG  collection ..................... 48  
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  5 INVESTIGATOR PROTOCOL AGREEMENT  
CPP FAP-310 
A DOUBLE-BLIND, RANDOMI ZED, PHASE III TRIAL OF THE SAFETY AND E FFICACY OF CPP-
1X/SULINDAC COMPARED WITH CPP-1X, SULINDAC AS SINGLE AGENTS IN PATIENTS WITH 
FAMILIAL ADENOMATOUS POLYPOSIS (FAP)  
By [CONTACT_31300], I agree: 
1. That my staff and I have rea d, understand and will adhere to  the protocol as written and agree 
that any changes to the protocol will be agreed to and approved  by [CONTACT_799345], except to eliminate an immediate hazard to the  patients.  Prior to instituting 
changes, I will obtain approval from the Independent Ethics Committee (IEC)/Institutional 
Review Board (IRB)/Research Ethics Board (REB); 
2. To abide by [CONTACT_89040] 1572 and other documents required by 
[CONTACT_5151]; 
3. To conduct this study in accordance with the current Interna tional Conference on 
Harmonization (ICH) guidance, the  Good Clinical Practices (GCP)  guidance the US FDA 
regulations, EMA regulations, Health Canada regulations, local competent authority 
regulations, and local IRB/IEC /REB and legal requirements; 
4. To obtain IRB/IEC/REB approval of the protocol, any amendments to the protocol, and 
periodic re-approval as require d, and to keep the IRB/IEC/REB i nformed of adverse events 
and periodically report the status of the study to them; 
5. To ensure that each patient enr olled into the trial, or lega lly authorized representative has 
read and understands the curren t patient information, and has s igned the Informed Consent 
form; 
6. To ensure that I and all pers ons assisting me with the study are adequately informed and 
trained about the investigati onal drug and of their study relat ed duties and functions as 
described in the protocol; 
7. To make prompt reports of Se rious Adverse Events (SAEs) and deaths as defined in the 
protocol, the FDA regulations, EMA  regulations, local competent  authority regulations, and 
Health Canada regulations; 
8. To prepare and maintain adequate and accurate case histories  to document all observations 
and other data pertinent to the study on each individual enroll ed in the clinical trial. 
Investigator Signature:  ________________________________________  ________________   Date  
Investigator Name (Print):  _____________________________________ Institution:  _________________________________________________ _ 
 __________________________________________________  __________________________________________________ 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  6 1. GENERAL INFORMATION 
 Protocol Title 
A Double-Blind, Randomized, Phase  III Trial of the Safety and E fficacy of CPP-1X/Sulindac 
Compared with CPP-1X, Sulindac as Single Agents in Patients with Familial Adenomatous 
Polyposis (FAP)  
 Sponsor and Study Monitor 
Cancer Prevention Pharmaceuticals, Inc. [ADDRESS_1102566] Tucson, AZ [ZIP_CODE] Phone: +[PHONE_16687] Fax: +[PHONE_16688]  Study Coordinator and Medical Monitor Alfred M. Cohen, M.D., F.A.C.S., F.A.S.C.R.S. Chief Medical Officer Cancer Prevention Pharmaceuticals, Inc. Email: [EMAIL_15216] 
Phone (Main): +[PHONE_16687] Phone (Cell): +[PHONE_16689]  Legal Representative EU Cancer Prevent Pharma Ltd   Andrew B. Hadlington, Wessex Pharma  Services Ltd 
Tower 42, Level [ADDRESS_1102567], Winchester, International Finance Center 25  Hants SO22 5NT 
London ECN2 1HQ [LOCATION_008] Phone/Fax: [PHONE_16696] 
Mobile: [PHONE_16697] 
 
  SAE Reporting, Reporting Contact [CONTACT_799346]. 
Chiltern Drug Safety contact [CONTACT_3031]: Phone: [PHONE_16690] (US/Canada); 001 ([PHONE_16691] (EU) Fax: [PHONE_16692] (US/Canada); 001 ([PHONE_16693] (EU) Email: [EMAIL_15217]  
 CPP Phone Contact [CONTACT_7171]: Monday – Friday (8:00 am – 5:[ADDRESS_1102568]), Phone: +1 (520) 908-77 74; Fax: +[PHONE_16688] 
 Alternative CPP Contact [CONTACT_149631]: Alfred Cohen, M.D., cell: +[PHONE_16689] or Kathryn Grenier,  cell: +[PHONE_16694] 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  7 
 Other Medical and/or Technical Departments 
Biostatistician 
Bruce Levin, Ph.D. 
Professor, Department of Biostatistics,  Mailman School of Public Heal th, Columbia University 
[ADDRESS_1102569] 
Ann Arbor, MI [ZIP_CODE] [LOCATION_003] 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  8 Steve Gallinger, M.D., MSc, FRCS 
Professor of Surgery, Head, Division of  
Hepatobiliary/Pancreatic Surgical Oncology Prgm  
Robert Gryfe, M.D., PhD, Zane Cohen, M.D. 
Zane Cohen, Centre for Digestive Diseases 
Univ. Health Network and Mount Sinai Hospi[INVESTIGATOR_307] [ADDRESS_1102570]. MC 0990 
La Jolla, CA [ZIP_CODE] [LOCATION_003]  
Fiona Lalloo, M.D. Manchester Centre For Genomic Medicine 
Central Manchester University  Saint Mary’s Hospi[INVESTIGATOR_307]- Oxford Road Mancheste
r, M13 9WL [LOCATION_008] Giovanna da Silva, M.D. 
Cleveland Clinic [LOCATION_012] 
[ADDRESS_1102571] Madison, WI [ZIP_CODE] [LOCATION_003]
William Grady, M.D. Fred Hutchinson Cancer Research Center /University of Washington [ADDRESS_1102572] South 
Medical Arts Building, Room 711 Nashville, TN [ZIP_CODE] [LOCATION_003]   
 
  
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  9 
 Study Schema 
MAJOR ELIGIBILITY CRITERIA 
1. Diagnosis of Familial Adenomat ous Polyposis (FAP) with confirme d APC mutation AND age ≥ [ADDRESS_1102573] 3 years since colectomy/proctocolectomy with ileo-rectal 
anastomosis (IRA) or pouch. 
Disease at One or More of These Sites 
1. Intact colon (pre-colectomy) 2. Rectal/Pouch Polyposis 3. Du odenal Polyposis 
Stratification  
Stratification based on FAP-rela ted time to first event prognos is. 
1. best (i.e., longest projected time to first FAP-related event) – rectal/pouch polyposis 
2. intermediate – duodenal polyposis 
3. worst – pre-colectomy 
If a subject has two or more of these disease sites, the stratum for randomization will be 
according to the most severe prognosis stratum as defined above . 
Randomization 
A total of 150 subjects, drugs are taken once daily.  
 
 
 
 
Randomized subjects will receive 24 months of treatment and com plete their final assessment or come off-
study for an FAP-related event or for other reasons (for exampl e, safety issues, non-compliance, withdrew 
consent, lost to follow-up).  
Subjects completing 24 months of treatment without an FAP-relat ed event may continue on treatment for 
up to 48 months based on their randomization date as follows: 
1. If randomized between November 2015 and April 2016 eligible for  up to 36 months of treatment 
2. If randomized between May 2015 and October 2015 eligible for up to 42 months of treatment 
3. If randomized between July 2014 a nd April 2015 eligible for up to 48 months of treatment 
or until one of the following occurs: 
1. Subject has an FAP-related event or comes off study for other r easons 
2. Trial end-date of April 30, [ADDRESS_1102574] accrued prior to April 30,  2019 and an earlier trial end-date 
has been set by [CONTACT_13099] r and reviewed by [CONTACT_1363] 
5. An earlier trial end date prior to April 30, 2019 has been reco mmended by [CONTACT_799347]-1X (750 mg) CPP-1X (750 mg) Placebo (CPP-1X) 
 +    +    +   
Sulindac (150 mg) P lacebo (Sulindac) S ulindac (150 mg) 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  10 2. BACKGROUND INFORMATION 
 Natural History, Current Surgical and Endoscopic Treatment 
Familial Adenomatous Polyposis (FAP) is a syndrome caused by [CONTACT_799348] ( APC ) tumor suppressor gene and propagated by [CONTACT_799349]. Details of this syndrome can be found at OMIM ®, (Online Mendelian Inheritance in 
Man), http://www.ncbi.nlm.nih. gov/entrez/dispomim.cgi?id=175100 , which is an authoritative 
listing of human genes and geneti c phenotypes. This database is available to users’ courtesy of 
NCBI, the National Center for  Biotechnology Information.  
FAP is caused by [CONTACT_89483]/deletions in the APC  gene, which is located on chromosome 5q21-
q22.  Gardner syndrome is a variant of FAP in which desmoid tum ors, osteomas, and other 
neoplasms occur together with multiple adenomas of the colon and rectum 
(http://www.cancer.gov /cancertopi[INVESTIGATOR_1102]/pdq/gene tics/colorectal/Hea lthProfessional/page4/AllPages). 
Most FAP patients will have hundreds to thousands of colorectal  adenomas, and without 
prophylactic surgery develop colore ctal cancer before the age of 40.  Prophylactic surgery may 
involve total abdominal colectomy  with ileal-rectal anastomoses  (IRA), accompanied by [CONTACT_799350]/laser ablation  as needed.  Patients with 
extensive rectal involvement unde rgo total proctocolectomy with ileal pouch-anal reconstruction.  
Despi[INVESTIGATOR_799286]-risk  organ, many patients develop duodenal neoplasia (bulky 
adenomas/cancer) and require additional localized or Whipple ra dical surgery.  The Spi[INVESTIGATOR_799287] (Stage 3 or 4)[ADDRESS_1102575] likely to 
progress to cancer.  Bulow and colleagues2 reviewed duodenal polyposis issues in FAP patients.  
Gastric antral adenomas may occu r and rarely are symptomatic or progress to cancer.  
Despi[INVESTIGATOR_799288], approximately 50% of patients will develop adenomatous lesions in the neo-rectum.
3-[ADDRESS_1102576] a residual rectum after tota l colectomy require frequent 
surveillance, polypectomies and ablations for continuing rectal  polyposis. 
Desmoids are “benign tumors” (myo fibroblastic) and cause signif icant morbidity and mortality in 
some patients.  They are not asso ciated with any specific FAP g enotype but are more common if 
the APC mutation is distal to codon 1444; the major clinical risk factors are family history and prior colectomy.  Women are at gr eater risk. Growth of these lesions, particularly when they 
involve the root of the mesenter y, can lead to extensive surger y, often resulting in resection of 
ileal pouches and permanent ileo stomy.  Current treatment invol ves surgery, radiation, NSAIDS 
and anti-estrogens.  None of thes e approaches have major impact  on the growth of these lesions.
7-
9 Although an important site of disease and morbidity for FAP pa tients, this protocol will focus on 
intestinal polyposis only. 
Vasen and colleagues10 provide evidence-based guidelines for the evaluation and manag ement of 
FAP patients and provides detailed natural history data. After prophylactic colectomy, all FAP patients undergo regular surveillance intervention, with 
proctoscopy and upper GI endoscopy every 6-12 months.  Surgical  intervention may be required 
for progressive FAP related dis ease (defined in protocol).  We believe that disease control with 
our combination regimen will delay the occurrence of clinically  meaningful events. 
 Pharmacologic Clinical Trials in FAP Patients 
In the general population, certa in types of colorectal polyps h ave increased risk of progression to 
colorectal cancer.  High risk polyps (polyps with villous histo logy, size ≥1 cm, high grade 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  11 dysplasia, or multiple adenomas defined as 3 or more) have beco me the focus of colorectal 
tumorigenesis research due to th e higher rate of malignant pote ntial for these.11-15  The biology of 
common colorectal cancer is similar to the FAP phenotype.  Wallace and Lynch16 summarized the 
current status of chemoprevention in FAP patients.  The key dru gs/drug combinations are 
described below. 
 Sulindac Alone 
Labayle and colleagues17 studied 10 FAP patients with I RA in a randomized placebo contr olled 
double blind trial of sulindac 300 mg a day for 4 month intervals.  In rectal assessment of polyp 
counts, there was a statistical ly significant reduction with su lindac compared to placebo (despi[INVESTIGATOR_799289]). 
Nugent18 evaluated sulindac at 200 mg t wice a day in 24 patients with d uodenal neoplasia and in 
this group 12 had an IRA and the rectum was also evaluated.  This was a placebo controlled 
randomized trial.  Benefit was dem onstrated in the rectum, but treatment was not statistically 
beneficial in the duodenum. Giardello and his group
19 performed a randomized double b lind trial in non-operated FAP patients 
or those who had an IRA.  Sulindac at 150 mg twice a day was th e treatment regimen.  Rectal 
polyp numbers decreased 56% in the treated group. Tonelli et al.,
[ADDRESS_1102577] IRA for rectal polyp control with 150  mg of sulindac twice 
a day.  A major reduction in polyp numbers was demonstrated, bu t with a 50% incidence of 
gastrointestinal erosions. Giardiello and colleagues
22 utilized sulindac in 41 non-opera ted FAP patients, mean age of  13.  
By [CONTACT_799351] 3 of the 21 subjects randomized  to the sulindac arm were receiving 
150 mg of sulindac daily twice a day.  Treatment with sulindac for a four-year period was well 
tolerated.  Few adverse events w ere reported and 93% were grade [ADDRESS_1102578] was withdrawn 
because of possible drug-induced neutropenia.  The incidence of  any adverse event did not differ 
significantly between the sulindac group and the placebo group.   There was no demonstrable 
difference in the adenoma formation compared to placebo. 
 Celecoxib Alone 
Although FDA approved celecoxib for the treatment of FAP patien ts in 1999, [COMPANY_007] withdrew the 
agent’s registration.  Of note, this agent did not become a usu al part of standard care for these 
patients.  This is partly due to  concerns for patient safety re sulting from colorectal adenoma 
prevention studies reported in 2006.23,[ADDRESS_1102579]. 
Mark’s Hospi[INVESTIGATOR_307], London.
25,26  Patients were randomized to placebo control, celecoxib 100 mg  
twice daily, and celecoxib 400 mg twice daily.  In the Steinbac h report,25 6 months of celecoxib, 
400 mg twice daily showed a 28% change from baseline in the mea n number of rectal polyps, the 
lower dose of the drug (100 mg t wice daily) showed an 11.9% change in the mean number of 
polyps compared to baseline.  Sim ilar data were found in the duodenal cohort.  Polyp reduction 
with small baseline tumor burden was only 14.5%, but 31% in mor e involved baseline duodenal 
adenomatosis.  Again, effect was n oted only in the high dose ce lecoxib patients.  Sixty-eight 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  12 percent (68%) of patients in t he placebo group, 56% of patients in the 100 mg twice daily group, 
and 57% of patients in the 400 mg twice daily group reported one or more adverse events of grade 
2 or higher (NCI CTC, Ver. 3.0).  The most common events were d iarrhea and abdominal pain. 
 NSAIDs Plus Eflornithine Combination 
This research program was activ ated in 2002, as a randomized Ph ase II study (ClinicalTrials.gov 
[STUDY_ID_REMOVED]) comparing the effectiv eness of celecoxib +/- eflor nithine in FAP.  Accrual was 
discontinued after approximat ely 111 patients were entered.27,28_ENREF_26 
The stated purpose of this study was to “compare the effectiven ess of celecoxib with or without 
eflornithine in preventing colorectal cancer in patients who ha ve familial adenomatous 
polyposis”. The outcome measures involved changes in polyp numbers, polyp burden, and plaque-like duodenal polyps after 6 months of treatment.  This was a two-arm trial: 
1. Oral celecoxib (400 mg) twice da ily with oral eflornithine (500  mg/m
2), once daily, vs. 
2. Oral celecoxib twice daily and oral placebo once daily 
The major conclusions f rom that study were: 
• Addition of eflornithine, at an average daily dose of 750 mg (three 250 mg tablets) to celecoxib did not significantly reduce raw adenoma count according to primary endpoint measure (polyps in reference cluster in still color photos) compared to celecoxib alone.  
• At least borderline significance of the combination was achieved by [CONTACT_799352] 
(counts in photos, weighted by [CONTACT_799353], and by [CONTACT_799354]).  
• No deleterious ototoxicity due to eflornithine was detected.  
• No significant treatment-related adverse events were noted in e ither arm of the trial.  
• Finding of greater effect on diameter-weighted burden suggests these agents may have greater effect at level of adenom a promotion than initiation.  
• Based on findings from another trial, use of a web-based quantitative tool for capturing 
diameter-weighted adenoma counts from videos of total colon or rectum may be more 
informative than approaches to adenoma quantification to date.  
 Eflornithine Alone 
There are extensive preclinical studies in mouse models of FAP.  These mouse models express a 
mutant form of the mouse homol og of the human adenomatous polyp osis (APC) gene.  When 
these mouse models of FAP are treated with eflornithine alone, the agent causes a dose-dependent 
decrease in the number of both intestinal and colonic polyps.29-[ADDRESS_1102580] of  eflornithine, at an average daily dose 
of 750 mg in patients with FAP.28  There was no eflornithine alone arm in that trial, so the dat a 
only addresses eflornithine in co mbination with celecoxib.  How ever, in that trial there was 
evidence for both safety of eflo rnithine at 750 mg/day in this patient population (no difference 
between NSAID alone and the comb ination arm) and efficacy (stat istically significant effect of 
combination versus NSAID alone a rm) for both total polyp volume and global polyp burden 
measures. 
The major evidence for benefit of eflornithine derives from pro spective, randomized, placebo-
controlled clinical trials of e flornithine alone in patients wi th elevated risk for developi[INVESTIGATOR_799290].  In one trial of  81 men with a family history of prostate cancer, oral eflornithine 
alone (500 mg per day for one yea r) reduced prostate polyamine contents, prostate volumes and 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  13 prostate specific antigen (PSA ) doubling times in men, compared to these same parameters in 
men taking placebo tablets.32  In a second study, 291 people with prior non-melanoma skin 
cancers were treated with eflornithine alone (500 mg/m2 per day for 4-5 years).  In that study, the 
treatment with eflornithine was associated with a highly statis tically significant reduction in 
metachronous basal cell skin cancers.33  Toxicities were rare in bot h of these studies, and 
consisted of infrequent clinica lly non-significant ototoxicity (meaning that the ototoxicity was not 
apparent to the patient and was only detectable by [CONTACT_799355]).  A recent report 
of this eflornithine-related toxicity was reported in detail fo r a clinical trial evaluating the 
combination of eflornithine and sulindac.[ADDRESS_1102581] 
also been conducted with trial e ndpoints consisti ng of tissue p olyamine contents.  These markers 
are dependent on ornithine decarboxylase (ODC), the eflornithin e target protein.  Doses, such as 
those proposed by [CONTACT_1034], have been shown to reduce rectal  mucosal tissue polyamine 
contents in a randomized placebo-controlled clinical trial.35  This marker study is especially 
relevant to patients with famili al adenomatous polyposis (FAP),  where the target tissues include 
intestinal and colonic mucosa. 
These clinical trial results are corroborated by [CONTACT_799356][INVESTIGATOR_799291].  Examples of this type of evidence include studies 
replicated by [CONTACT_799357] a  polymorphism affecting the 
expression of ODC, the eflornith ine target protein, is highly a ssociated with metachronous colon 
adenomas36,[ADDRESS_1102582] reported 
that this same polymorphism is associated with prostate cancer39 and colon cancer survival.40 
 Sulindac and Eflornithine; Colorectal Polyp Chemoprevention 
Meyskens and colleagues41 performed a Phase III double-blind trial involving resected sp oradic 
adenoma patients treated for three (3) years with eflornithine (500 mg once a day) plus sulindac 
(150 mg once a day) compared to placebo/placebo that demonstrat ed a marked reduction (70%) 
of metachronous adenomas overall , 92% efficacy against advanced  adenomas, and 95% efficacy 
in decreasing the risk of developi[INVESTIGATOR_799292].  Additionally, this 
combination regimen was generally well-tolerated. 
 Biology Of Eflornithine 
Ornithine decarboxylase (ODC) is a  transcriptional target of th e MYC  oncoprotein and MYC  
transcription is suppressed by [CONTACT_799358].42,[ADDRESS_1102583].
45  Studies in animal models of FAP 
indicate that eflornithine alone is effective in reducing the n umber of intestinal29 and colonic30 
tumors.  Eflornithine works in combination with the non-steroidal anti-inflammatory drug 
(NSAID) sulindac to further reduce tissue polyamine contents, as sulindac activates polyamine export mechanisms.
[ADDRESS_1102584] been 
shown to reduce the number of ad vanced adenomas by [CONTACT_726] 90 % in mouse models of 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  14 FAP.31  These results provide strong r ationale that patients with FAP should respond to this 
therapy. 
 Rationale for Eflornithine Dose 
Prior pharmacokinetic (PK) studies  had documented linearity of serum eflornithine levels with 
oral doses as low as 100 mg/m2/day.[ADDRESS_1102585], in 
the range of 200-400 mg/m2/day as a dose range that effec tively reduced colorectal tissue  
polyamine contents.35  Oral doses in this range achieve serum concentrations that in hibit ornithine 
decarboxylase enzyme activity and polyamine synthesis in cell c ulture models.48  Based on these 
findings, a Phase III clinical t rial of eflornithine combined w ith the non-steroidal anti-
inflammatory drug (NSAID) sulindac was conducted to evaluate th e effect of this combination on 
the incidence of metachronous col orectal adenomas in patients w ith prior sporadic (non-genetic) 
colorectal polys.41  Based on an average adult body surface area of 1.6 m2,49 a dose of 500 mg 
oral daily dose of eflornithine was selected.  That study found  that the combination therapy 
reduced total metachronous color ectal adenomas by 70%, and advanced/multiple metachronous 
colorectal adenomas by [CONTACT_726] 90% while also reducing colore ctal polyamine levels.41,50  No 
clinically significant toxicities were found to be statistically significant in that study.  Clinically 
non-significant ototoxicities were  identified in less than 10% of patients, using quantitative 
audiology methods.[ADDRESS_1102586] reported results of a 
trial using 500 mg/m2/day eflornithine, rounded to the nearest 250 mg as 250 mg tabl ets were 
used in this study, combined w ith 400 mg BID celecoxib.  After correcting for body surface area, 
the average eflornithine dosage was three (3) [ADDRESS_1102587] of the combination was not different from celecoxib alon e for the primary endpoint 
(duodenal and colorectal polyp number), the Lynch et al. study provided evidence for 
effectiveness of the combinati on versus celecoxib alone (statis tically significant reductions in the 
secondary endpoints of polyp volume and global polyp burden).  No differences in toxicities, 
including ototoxicities, were observed between treatment arms in this study.  Another study in non-FAP patients but relevant to p otential safety issues of the  higher eflornithine dose has also 
been reported. Bailey and colle agues treated 291 patients with prior non-melanoma skin cancers 
with 500 mg/m
2/day eflornithine for 4-[ADDRESS_1102588] that they harbor germline mu tations in the adenomatous pol yposis coli (APC) tumor 
suppressor gene.  These genotypic FAP patients express higher l evels of the eflornithine target 
gene, ornithine decarboxylase (ODC) and polyamine contents in apparently normal rectal mucosa than do non-genotypic familial controls.
44  These levels are higher than those reported for patients 
with sporadic risk of colorectal cancer.51 
This study will use three (3) 250 mg eflornithine tablets daily  in CPP FAP-310.  This is based on 
both safety and efficacy consider ations.  Both the Lynch study (in FAP patients) and the Bailey 
study and others (in non-FAP patie nts) indicate safety of this eflornithine dose.28,33_ENREF_33   
The Lynch study provides evidence for efficacy of the higher ef lornithine dose in FAP patients.28 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  15 
 Rationale for Sulindac Dose 
The dose of sulindac (daily oral dose of 150 mg) for this study was selected on knowledge of its 
physiology and evidence from preclinical and clinical studies. 
Experimental findings in human ce ll and mouse models indicate that sulindac and other NSAIDS 
activate polyamine catabolism and export.43  Thus, NSAID complement inhibitors of polyamine 
synthesis, like eflornithine, to reduce tissue polyamines.  Cel l culture data demonstrated that 
sulindac metabolites reduce cell survival in vitro in a dose de pendent manner at doses above 
150µM for 24 hour exposure times.52 
Eflornithine-sulindac combinations are potent inhibitors of int estinal carcinogenesis in mouse 
models,31 Figure 1. 
 Figure 1 - Eflornithine-Sulindac Combinations Mouse Model 
 
Ignatenko, Nutrition & Cancer [ADDRESS_1102589] common side effects  being gastrointestinal and include pain, dyspepsia, nausea and 
gastrointestinal cramps. 
Clinical studies demonstrate that a range of orally administere d sulindac can cause regression of 
colorectal adenomas.  In the revi ew by [CONTACT_799359],54 sulindac doses from 100 – [ADDRESS_1102590] been shown to cause regre ssion of colorectal adenomas in 
patients with Familial Adenomatous Polyposis (FAP).  Sulindac s ide effects noted in most of 
these studies were minimal although at the 300 mg/day of sulind ac there may be an increase in 
cardiovascular risk in older high risk patients. The studies summarized in the Keller and Giardiello review prov ides the clinical data to support 
the use of low doses of sulindac are effective in reducing colo rectal adenoma burden in FAP 
patients
20,21,55,56,57,[ADDRESS_1102591] doses of suli ndac (300-400 mg) are associate d with 
significant toxicities.  Therefore , a low dose of sulindac (150  mg) once per day was selected to be 
combined with eflornithine for treatment of patients with Famil ial Adenomatous Polyposis that 
are at high risk of developi[INVESTIGATOR_799293]/intestinal cancer. Sulindac used off label is often the choice of clinicians treat ing FAP patients today.
59  A 
commonly used sulindac dose in progressive rectal polyposis is 150 mg twice a day; after a few 

IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  16 months and demonstration of regre ssion, dosage may be reduced to 150 – 200 mg daily (Burt, 
personal communication) or to [ADDRESS_1102592] as effective but requires a longer 
time to regression. 
 Summary of Known and Potential Risks 
 Cardiac Risk 
A recent pooled-analysis of cardiovascular events in six clinic al trials involving non-arthritis 
patients using celecoxib or placebo demonstrates that celecoxib  is indeed associated with a dose-
dependent increased risk of cardiovascular events60 – high dose, long duration.  In this analysis, 
three baseline cardiovascular r isk categories were proposed: lo w, moderate, and high, using 
clinical information obtained fro m routine medical assessment.  It was not known if these baseline 
cardiovascular risk assessments were associated with adverse ca rdiovascular events observed in 
the Phase III adenoma prevention trial of eflornithine plus sul indac (16 cardiovascular events 
occurred in this arm) compared with placebo (9 cardiovascular events occurred in the placebo  
arm).  Therefore, members of the UC-Irvine group61 performed detailed toxicity analysis of data 
from the Phase III eflornithine and sulindac versus placebo col orectal adenoma prevention trial, 
with a particular focus on base line cardiovascular risk assessment.  Cardiovascular toxicity 
outcomes were then reported wit h and without exclusion of high- risk patients from the analysis.  
In the original sample of 184 placebo and 191 eflornithine/suli ndac patients, respectively, 
baseline cardiovascular risk scores were evenly distributed (low: 27% vs. 30%, moderate: 34% 
vs. 29%, high: 39% vs. 41%).  A g reater number of patients with  high cardiovascular risk at 
baseline experienced events in t he eflornithine/sulindac arm (n =9) compared to placebo (n=3). 
When all patients with high baseline cardiovascular risk were excluded from the analysis, the number of cardiovascular events between the treatment (n=7) and  placebo (n=6) arm was 
similar.
[ADDRESS_1102593] a possibl e interaction be tween eflornithine/sulindac treatment and 
baseline cardiovascular risk score on cardiovascular events. 
 Ototoxicity Risk 
In the Meyskens eflornithine/su lindac Phase III randomized placebo-controlled colon adenoma 
prevention trial41, no significant differences in  hearing loss were noted compare d to placebo; 
however, minor differences in he aring loss attributed to eflornithine plus sulindac combination 
were observed in detailed longitudinal analyses.[ADDRESS_1102594] correlation due to 
repeated measurements at freque ncies.  Based on 290 subjects, t here was an average difference of 
0.50 dB between subjects treated w ith eflornithine plus sulinda c compared with those treated with 
placebo (95% confidence interval, −0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.  In the normal speech range of 500 to 3,000 Hz , an estimated difference of 0.99 
dB (−0.17 to 2.14 dB; P = 0.09) was detected.  Dose intensity d id not add information to models. 
There were 14 of 151 (9.3%) in the sulindac/eflornithine group and 4 of 139 (2.9%) in the placebo 
group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire ra nge tested (P = 0.02).  Follow- up air conduction done at least 6 
months after end of treatment s howed an adjusted mean difference in hearing thresholds of 1.08 
dB (−0.81 to 2.96 dB; P = 0.26) between treatment arms.  There was no significant difference in the proportion of subjects in the sulindac plus eflornithine gr oup who experienced clinically 
significant hearing loss compared with the placebo group.  The estimated attributable risk of 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  17 ototoxicity from exposure to the drug is 8.4% (95% confidence i nterval, −2.0% to 18.8%; P = 
0.12).  However, there is only a <2  dB difference in mean thres hold for patients treated with 
combination compared with those treated elsewhere (other trials ) with placebo. 
The eflornithine dose used in th e Meyskens [ADDRESS_1102595] recently updated their study of pa tients with prior non-
melanoma skin cancer that were treated with 500 mg/m2 (also rounded to the nearest 250 mg as 
they used eflornithine tablets) for 4-5 years.62  The Bailey study demonstr ated a signiﬁcant (P < 
0.05) increase in uniformly tra nsient audiometric (but not clin ically detectable) hearing loss in 
participants on eflornithine.[ADDRESS_1102596] insert (Actavis, formerly Watson Laboratories, Inc.)[ADDRESS_1102597] of 
practice involves prophylactic col ectomy or proctocolectomy, followed by [CONTACT_799360]/or laser/cautery a blation every 6 – [ADDRESS_1102598] extensive polyposis at  a young age and require surgery 
prior to entering college.  Following prophylactic colon surger y, follow-up intervention by 
[CONTACT_799361] 6 – 12 months a nd subsequent surgical 
interventions are generally performed at experienced centers of excellence, requiring frequent, 
inconvenient and expensive travel.  The serial interventions ar e unpleasant, require dietary 
restriction and enemas.  During surgical procedures, some patie nts require general anesthesia and 
all patients require sedation.  S urgical procedures for large o r multiple adenomas may involve 
snare cautery polypectomy or tra ns-anal excision and carry risk of bowel perforation and or 
subsequent bleeding.  The greater  the frequency and extent of t he surgical procedures, the greater 
the morbidity and associated cos ts.  Such interventions frequen tly result in reduced compliance 
with medical and surgical recomme ndations, with subsequent incr eased likelihood of the 
development of an interval cancer.  In addition, repeated cautery ablations lead to scarring and impaired bowel function over the years. 
A major goal of this program is to defer or obviate the need fo r additional surgical interventions 
in patients with familial adenomatous polyposis.  In patients t reated with total abdominal 
colectomy with ileo-rectal anastomoses, the addition of sulinda c combined with eflornithine has 
the potential to defer or eliminat e the need for a complete pro ctectomy by [CONTACT_799362]. 
Prophylactic proctocolectomy does not “cure” patients with this  genetic syndrome. FAP related 
disease remains a major problem in the residual rectum, pouch, anal transition zone, duodenum 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  18 and desmoid formation; both can lead to major morbidity and mortality.  Surgical intervention is 
marginally effective,  and there are no appr oved pharmacotherape utic agents. 
Fifty percent (50%) of patients following total proctocolectomy  with ileal pouch anal 
reconstruction develop adenomas i n the pouch and require the sa me extensive follow-up 
evaluations and surgical treatment s.  Almost all FAP patients are at risk for progressive duodenal 
adenomatous polyposis which can lead to extensive and frequent surgical endoscopic procedures 
and/or major surgical resecti ons.  Duodenal polyposis is a majo r cause of morbidity, mortality, 
patient inconvenience and health  care costs in FAP patients.  N inety percent (90%) of patients 
with FAP develop duodenal polyposis2 for which there is no approved pharmacologic agent to 
control this disease.  Five (5) to 10% of patients have Spi[INVESTIGATOR_799294] 4 on screening endoscopy; 
one-third of these patients develop cancer.  Of greater concern  from the Bulow analysis is that 
52% of patients with duodenal pol yposis who start with Stage 1,  2 or 3 will progress to Stage 4; 
the standard of care for Stage 4 is to consider some type of ra dical surgical intervention.  The 
complexity of managing such pati ents is well described in the d efinitive review of FAP 
management guidelines by [CONTACT_799363].10  The marginal benefit of endoscopic 
management of the duodenum is reviewed and tabulated (Table 4) in the paper by [CONTACT_799364].65  The data clearly demonstrate the need and potential efficacy of the pharmacologic 
control of duodenal polyposis; us ing the well-established Spi[INVESTIGATOR_799295] n, along with pre-malignant h istology.  The mai n determinant of 
Stage 4 is the presence of villous adenoma or high grade dyspla sia on staging biopsies – objective 
measures of pre-cancerous risk.  
Increasing the time to clinically  meaningful endpoints relevant  to standard of care by [CONTACT_799365]-related events (FAP-related surgery, duodenal polyposis, cancer and 
death) are key factors in rega rd to the morbidity and mortality of this genetic disease.  FAP 
related surgical or clinical eve nts in the rectum or pouch include surgery related to large or high 
risk adenomas or cancer; for FA P disease in the duodenum it inc ludes surgery for enlarging or 
high risk adenomas. After IRA surgery, pharmacologic c ontrol may mini mize the need for additional rectal surgery 
(surgical snare excisions of polyps greater than 5 mm; surgical  trans-anal excision of rectal 
polyps; proctectomy) and/or mini mize development of pre-cancero us adenoma (dysplastic polyps, 
villous adenoma) and cancer.  After pouch surgery it may minimi ze need for additional surgery 
(surgical snare excision of polyps greater than 5 mm, surgical trans-anal excision of rectal polyps, 
pouch resection with ileostomy) and/ or minimize development of pre-cancerous adenomas and 
cancer. In FAP patients with duodenal polyposis, pharmacologic control may suppress development of 
further polyposis, slow or prevent progression to Spi[INVESTIGATOR_799296] 3 and 4 disease, minimize 
progression to dysplastic polyps or  villous adenomas, minimize polyposis involving the Ampulla 
of Vater, minimize development of cancer o r reduce the need for procedures such as snare 
polypectomy, submucosal excisions , trans-duodenal excisions, du odenectomy, Whipple 
(pancreatic duodenectomy) or related procedures. Pharmacologic control in FAP patients has major implications fo r clinical benefit to reduce the 
morbidity of the disease and the reby [CONTACT_799366].  The use of low dose 
sulindac and CPP-1X may prolong t he time to occurrence of clinically important FAP-related 
disease events (FAP related event s include surgical procedures and progressive advanced 
intestinal polyposis).  
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  19 In addition to the above, the combination drug regimen may prov ide additional clinical benefit by,  
• Deferring the initial prophylactic  colectomy to a more “conveni ent time” such as after 
graduation from school or after childbirth. 
• Increasing the use of colectomy with ileal-rectal reconstructio n rather than total 
proctocolectomy which results in improved quality of life in re gard to bowel function and 
reduces the risk of loss of fertility in women. 
• Reducing the risk of progressive  rectal/pouch polyposis that re quires surgical intervention. 
• Reducing the risk of rectal stu mp/pouch-related post polypectomy scarring with loss of 
bowel function (absence of compliant rectal reservoir). 
• Deferring or obviate the need for pouch removal with need for permanent ileostomy 
stoma. 
• Deferring or obviate the need for  surgical intervention for adv anced duodenal polyposis 
with associated morbidity and mortality. 
• Improving health-related quality of life (HRQoL). 
 
 Rationale for Treatment Duration Extension up to 48 Months 
The initial statistical analysis plan used detailed event rate projections based on an extensive 
review of the published literature (Refer to Appendix E) and de termined that a sample size of [ADDRESS_1102599] etion of the trial with a maxim um of 24 months of treatment.  
Based on this analysis, it was considered unlikely we would rea ch the projected 90 events before 
the end of the study.  To reduce the risk of a false-negative t rial (because of inadequate events 
after two years of study treatment in 171 randomized subjects), several mitigation options were 
explored.  The protocol was ame nded to extend treatment duration to a maximum of 36 months. 
Over 90% of subjects who reached [ADDRESS_1102600] rate assumptio ns to maintain  power > 85%, an additional trial 
extension may be required.  This protocol amendment offers all active subjects a longer-term 
blinded treatment until study completion at or before April [ADDRESS_1102601] 
been no recommended protocol modifications due to safety.  Additionally, for CPP FAP-310, the 
Medical Monitor performs a monthl y blinded review of all adverse events to evaluate for events 
not commonly associated with drug exposure or to look for an in crease in events above what is 
typi[INVESTIGATOR_799297]. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102602] been twenty-six (26) serious 
adverse events (SAEs) that have  been reported from the CPP FAP- 310.  Two events were 
classified as S[LOCATION_003]Rs; however , no subject treatment arm assignments were unblinded.  
Twenty-one (21) of the twenty-six (26) SAEs were classified as not related to study treatment by 
[CONTACT_30967].  There were eleven (11) gastrointestinal events. These included five (5) 
small bowel/intestinal obstructions.  This type of event is not  uncommon in the FAP population, 
particularly those with multiple surgeries.  There was one (1) gastrointestinal events of ileus and one (1) ileal stricture.  The subject with ileus had additional epi[INVESTIGATOR_799298].  Ileus and ileal s tricture are expected events in the FA P and post colon surgery patient 
populations.  There was also one ( 1) event of rec tal bleeding t hat was from a post-polypectomy 
ulceration.  Bleeding is a common complication from an endoscop ic excision and there was also 
one (1) procedural complicati on that involved a post-polypectomy bleed.   
There was one (1) event of panc reatitis in a sub ject with a pri or history of pancreatitis and one (1) 
subject with acute pancreatitis .  The subject with pancreatitis  was hospi[INVESTIGATOR_799299] a life-threateni ng, grade 4 serious adverse event .  In the case of acute pancreatitis, 
the investigator indicated that the likely cause was ampullary adenomatous disease.  FAP patients are at a higher risk of pancrea titis than the general populatio n
66.  Pancreatitis is a rare, but 
identified risk of sulindac.  The Investigator’s Brochure, Suli ndac package Insert and published 
reports indicate that pancreatitis is asso ciated with the use o f sulindac.67 
One (1) subject experienced grad e [ADDRESS_1102603] of both eflornithine and 
sulindac as documented in the Inve stigator’s Brochure, the inve stigator evaluated as not related 
due to the timing and rapid r esolution of the event. 
There was one (1) event in the nervous system disorders categor y that was a seasonal migraine in 
a subject had a history of this type of event.  For neoplasms, there was one (1) diagnosis of lung adenocarcinoma with a brain les ion, unrelated to treatment.  Th ere was also one (1) event of 
chronic myeloid leukemia, unrelat ed to treatment. In addition to the post-polypectomy bleed 
described above, there were thr ee other (3) events in the injur y/complications category.  There 
was one (1) wound complication re lated to cellulitis of an inca rcerated umbilical surgical scar. 
This was unrelated to study trea tment and relate d to multiple p rior surgeries. One (1) event of 
seroma complication post-desmoid s urgery was unrelated to treat ment and is a known 
complication of abdominal surger y.  The one (1) event of anasto motic stricture was a 
hospi[INVESTIGATOR_799300] a pre-existing anal stenos is and was unrelated to treatment.  
One subject had perforated knee bursitis, likely infectious in origin, that was classified as 
unrelated to study medication.  One  (1) subject with pre-existi ng COPD experienced an 
exacerbation that required medication and oxygen therapy, but w as not related to treatment.  The 
subject with acute pancreati tis described above also experienced grade 3 hyperglycemia and was 
diagnosed with type 2 diabetes.  T his event was unlikely to be related to treatment, but is reported 
to be a very rare complication of sulindac and is listed in the  Investigator’s Brochure.  
The remaining five (5) events w ere classified as being possibly  (4) or probably (1) related to 
treatment.  One (1) event of w orsening of depression was listed as possibly relat ed to treatment.  
Depression is covered in the Reference Safety Information as a known side effect of sulindac and 
with the side effect of emotional lability for eflornithine.  F or vascular disorders, there was one 
(1) thromboembolic event (DVT w ithout pulmonary embolism) liste d as possibly related to 
treatment.  This is a known risk of sulindac and is listed in t he Reference Safety Information in 
the Investigator’s Brochure.  One (1) subject experienced sever e nausea (grade 3) approximately 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  21 4 months after study treatment began.  This was possibly relate d to treatment; nausea is listed as a 
complication of both eflo rnithine and sulindac. 
There were two (2) events that w ere classified as S[LOCATION_003]RS.  One (1) subject experience psychosis 
and paranoia, grade 3.  This began 6-[ADDRESS_1102604] had a history of miscarriage and the event was 
classified as possibly related.  T he Sponsor determined that th e SAE of spontaneous abortion was 
not related to the study medicati on.  Eflornithine is known to be embryotoxic in animal studies 
and is listed as a safety risk i n the Investigator’s Brochure.  
The constituents for this combination therapy, eflornithine and  sulindac, are considered as having 
well-established medicinal use wi thin the meaning of Annex I to  Directive 2001/83.  Both active 
substances have been authorized i n medicinal products for vario us therapeutic indications for 
doses, duration and frequency exceeding that which is used in the CPP FAP-[ADDRESS_1102605] minimal t oxicities when used for treatme nt periods of 3 or more years in 
patients with risk of cancer.  The  minimal toxicities observed to date in CPP FAP-310 for 
treatment of FAP patients with eflornithine and sulindac for up  to 3 years supports the extension 
of the treatment time in CPP FAP-310 from 3 to up to 4 years at a dose level of 750 mg/day eflornithine and 150 mg/day sulindac. 
This protocol amendment may exte nd the trial by [CONTACT_8622] 12 months , and offers subjects (based on 
their randomization da te) treatment up to [ADDRESS_1102606] reasons unrelated to FAP- related endpoint indicators, or the 
final end of study date. In the absence of an FAP-related event , subjects will receive study 
treatment for 24 to 48 months. T he final decision concerning the trial end-date if prior to April 30, 
2019, will be based on accrued FA P-related primary endpoints, n umber of subjects still active on 
trial, FAP event projections, and additional safety reviews. As suming continued acceptable safety 
profile, this approach will mini mize the risk of a false negati ve trial. 
 Purpose 
This randomized, double-blind, phase III trial will compare the  efficacy, safety and 
pharmacokinetics of the CPP-1X/sulindac combination versus CPP- 1X and sulindac as single 
agents with up to a 48-month maxi mum treatment period in patients with Familial Adenomatous 
Polyposis (FAP). 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  22 4. INVESTIGATIONAL PLAN 
 Study Population 
• Diagnosis of phenotypic classical FAP, age ≥[ADDRESS_1102607] be 
genotyped, with an APC mutation.  Refer to Section 6.1 for deta ils. 
• Meets eligibility criteria for at  least one FAP related disease  group defined in Section 6.1. 
• If prior colorectal surgery, at least three years since colecto my with ileal-rectal 
anastomosis (IRA) or total procto colectomy with ileal pouch-ana l reconstruction (pouch). 
• Absence of major cardiac risk factors as defined in Section 6.2 . 
• Absence of clinically significan t hearing loss requiring a hear ing aid. 
• Adequate laboratory studies (hem atology, chemistry, and urinalysis) at study entry. 
 Treatment 
• Experimental arm: 750 mg CPP-1X, and 150 mg sulindac 
• Comparator arms:  
1. CPP-1X placebo with sulindac (150 mg) 
2. CPP-1X (750 mg) with sulindac placebo 
• Treatment is administered as four tablets taken once daily with  food (same time of day, 
preferably in the morning), for up to 48 months. 
• Randomized subjects will receive 24 months of treatment and complete their final 
assessment or come off-study for an FAP-related event or for ot her reasons (for example, 
safety issues, non-compliance, with drew consent, lost to follow -up).  
• Subjects completing 24 months of treatment without an FAP-relat ed event can continue on 
treatment for up to 48 months based on their randomization date  as follows: 
1. If randomized between November 2015 and April 2016 eligible for  up to 36 
months of treatment 
2. If randomized between May 2015 a nd October 2015 eligible for up to 42 months 
of treatment 
3. If randomized between July 2014 and April 2015 eligible for up to 48 months of 
treatment 
or until one of the following occurs: 
1. Subject has an FAP-related event or comes off study for other r easons 
2. Trial end-date of April 30, [ADDRESS_1102608] accrued prior to April 30,  2019 and an 
earlier trial end-date has been set by [CONTACT_799367] 
5. An earlier trial end date prior to April 30, 2019 has been reco mmended by [CONTACT_799368] 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102609] 150 eligible patients will be enrolled in this study.  Subjects will be randomized to one of 
three treatment groups in equal proportions (i.e., 1:1:1 randomization): 1) CPP-1X plus sulindac 
2) CPP-1X - placebo plus sulindac, 3) CPP-1X plus sulindac placebo. 
A stratified randomization proce dure will be used with stratifi cation based on FAP-related time-
to-first-event prognosis.  The e vent prognosis groups are repre sented by 1) best (i.e., longest 
projected time to first FAP-rela ted event) - rectal/pouch polyp osis, 2) intermediate - duodenal 
polyposis, and 3) worst - pre-colectomy.  If a subject has two or more of these disease sites, the 
most severe prognosis stratum will be assigned for randomizatio n (e.g. worst > intermediate > 
best).  Since an individual may have more than one disease site  involved, the trial will assess time 
to any defined FAP-related even t in the subject as a whole. In order to minimize potential 
treatment arm imbalance a central ized randomization process will be used to balance among 
treatment groups within  prognostic strata. 
 Primary Outcome 
The primary objective of this tria l is to determine whether the  combination of CPP-1X plus 
sulindac is superior to either treatment individually, in delay ing the time from the date of 
randomization to the date of the first occurrence of any FAP-re lated event in the subject as a 
whole.  This includes: 1) FAP related excisional intervention i nvolving the colon, rectum, pouch, 
duodenum and/or 2) clinically impor tant events which includes progression to more advanced 
duodenal polyposis (Stage 2, 3 or 4), cancer or death.  Section  8.2.14 provides complete detail. 
 Secondary Outcomes 
Secondary Efficacy Analyses: Any improvement observed by [CONTACT_799369] (UGI) and lower 
gastrointestinal (LGI) visuali zation (i.e. endoscopy and colonoscopy) at the 6 and 12-month study 
visits will be described using th e variables UGI Observed Improvement (UGIOI), and LGI 
Observed Improvement (LGIOI).  E ach patient will have one pair of UGIOI and LGIOI outcomes 
(refer to Protocol Section 12.[ADDRESS_1102610] an for more detail). 
Other Secondary Outcomes in thi s Study Include the Following: 
To explore how study treatment group relates to o ther efficacy outcomes, genotype, phenotype, 
disease locations and endoscopic findings, additional analyses are planned (refer to the Statistical 
Analysis Plan for more details).   The UGIOI and LGIOI outcomes will be tabulated and summarized u sing the month 6 visit 
scores, alone.  Similarly, the UGIOI and LGIOI outcomes will ta bulated and summarized across 
all study visits. As both part of the primary analysis, and further explored in these additional analyses, median 
time to event for each treatment  group will be determined.  This will be explored for each of the 
study populations (i.e. ITT, per protocol, and others), study d isease stratum groups, and in the 
disease site subgroups. 
Pharmacokinetic data (plasma concentrations measured at patient visits) will be used to estimate 
population pharmacokinetic paramet ers for the CPP-1X (eflornith ine), sulindac, and CPP-1X 
(eflornithine) + sulindac treatment groups (i.e., for each anal yte for those patients on combination 
treatment). 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  24 The subcategories of FAP events will be explored by [CONTACT_799370], and by [CONTACT_799371].  
The presence or absence of ODC polymorphisms, including the sin gle nucleotide polymorphisms 
(SNPS) rs2302615 and rs2302616 and th eir relation to treatment group and outcome will be 
tested with the likelihood ratio test. The excretion of 5 urinary polyamines (diacetylspermine, n1-ace tylspermidine, n8-
acetylspermidine, decarboxylated SAM, and putrescine) will be a ssessed in relation to treatment 
group and outcome, using the sin gle point concentration data ga thered from the urine samples 
harvested at each study visit. Patient reported health related quality of life measures will b e evaluated using HRQoL.  
Tissue and dietary polyamine levels, as collected at patient st udy visits will be analyzed together 
with the results of the dietary questionnaires and related to treatment group and study outcomes. 
Safety outcome data and analyses are described in detail in the Statistical Analysis Plan. 
 Population Pharmacokinetics for CPP-1X/Sulindac 
All subjects consented, enrolled, and randomized in this study will have pharmacokinetic samples 
drawn at their scheduled 3-month visit.  All subjects will have  samples drawn on the same 
schedule regardless of treatment  arm assigned.  The samples will be obtained before first morning 
dose, then four additional sample s over the following eight hou rs. 
 Polyamine Analysis 
At each colonoscopy/proctoscopy while on study treatment, a sam ple of normal rectal mucosa 
and a random urine sample will be obtained to assess tissue and urine polyamine levels.  Sample 
handling and processing procedures will be provided in the stud y manual, are described here 
briefly. 
Biospecimen collection: Normal (tumor-free) rectal mucosal biop sies will be obtained during 
endoscopy procedures.  Biopsy samples will be placed in separat e standard cryotube tubes and 
stored in a -70 – 800C freezer.  Random urine samples (15 mL minimum) will be collec ted and 
stored in a -70 – 800C freezer. 
Polyamine content: Polyamine ana lysis will be performed as desc ribed previously.35  Briefly, 
frozen tissue samples will be homogenized and extracted in 0.2 N perchloric acid.  Urine samples 
will be adjusted to 0.2 N perchloric acid.  Polyamine (spermidi ne, spermine, and putrescine) 
content will be measured using re verse-phase, ion-paired high p erformance liquid 
chromatography.  Protein contents will be determined using the bicinchoninic acid protein assay 
(Thermo Fisher Scientific, Rockford, IL).  The spermidine-to-spermine ratio (Spd:Spm) will be assessed in our analyses to minimize the influence of assay variability.
35,68 
Dietary polyamines: Data will be collected using the Fred Hutch inson Cancer Center food 
frequency questionnaire and will be analyzed using a polyamine database.  Average daily consumption of putrescine, sperm idine, and spermine will be cal culated.
69  
 Pharmacogenetic and Genetic Analysis 
A peripheral blood sample will be  collected from enrolled subjects at baseline for subsequent 
correlative genomic studies relevant to this disease and in the  event treatment-related adverse 
events are discovered during the trial. Sample handling and pro cessing procedures, which will be 
provided in the study manual, are described here briefly. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  25 DNA extraction and genotypi[INVESTIGATOR_007]. DNA will be extracted from perip heral blood samples using the 
QIAGEN QIAamp DNA Midi or Mini K its (Qiagen), following the man ufacturer's instructions. 
Genotypi[INVESTIGATOR_799301]1 (National Center for Biotechnology Infor mation SNP database ID 
rs2302615) +316 SNP will be conducted using a PCR amplification of the targeted region and bi-
directional cycle sequencing of purified target amplicon using PCR/Sanger sequencing primers.  The sequencing reaction will be analysed on an Applied Biosystems [ADDRESS_1102611] and reverse dire ctions to confirm the SNP. 
 Quality of Life 
Assessment of Health-Related Quali ty of Life (HRQoL) is to bett er understand and quantify the 
impact of each treatment arm on FAP-related physical and emotio nal symptoms as well as FAP-
related surgical sequelae.  Specifically, postponing surgery because of reduction of polyps could lead to both symptomatic relief as well as reduced stress and w orry about cancer, future surgery 
and/or suffering of FAP-related m edical and surgical symptoms.  As such, several well-accepted 
and previously published questionn aires have been selected for use in the CPP FAP-310 trial. 
These include the EORTC core questionnaire, QLQ-C30,
70 the GI-specific sub-module, QLQ-
CR29,71 and the EQ-5D health utilities index.72,73  These instruments hav e all been previously 
used in gastrointestinal/colorec tal clinical trials and have be en validated and translated to ensure 
appropriate cultural/linguistic adaptation suitable for a multi -center, internationa l clinical trial. 
Also being used is a modified version of the Cancer Worry Scale .74 
 
  
IND 103,678  Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac ) 
CPP FAP -310 Ver. 5.2, 1 7January2019   27 ≥15 dB hearing loss at two adjacent frequencies (p=0.07).   The observed audiometric 
abnormalities were usually reversible; 19% and 18% of eflornithine  and placebo sub jects had 
persistent abnormal audiograms 6 months after stoppi[INVESTIGATOR_11743].33  
Infrequent side effects:   Hearing loss /change by [CONTACT_799372] 8.4% of 
patients on high dose eflornithine .  Rash and alopecia have been reported in 3% of patients.  
Anorexia and abdominal pain have been reported in 2% of patients treated with e flornithine.  
Rare but serious side effects include d izziness (1%), he adaches (2%), and seizures (8%)  have 
been reported in patients on intravenous eflornithine.  Myelosuppression (including leukopenia, 
[37%], anemia [55%], and thrombocytopenia [14%]) has been reported at high intravenous doses, 
but does not usually occur at the low dose ( 750 mg) utilized in this study.33 
Pregnancy and Lactation:   Pregnancy C ategory C. It is unknown if eflornithine crosses the 
placen ta.  Case reports in humans along with animal studies (mice, rats) indicate potential for 
fetotoxicity.  Experiments in rodents indicate that eflornithine blocks yolk sac formation and 
trophoblast differentiation, affecting processes s uch as vasculogenesis  and steroi dgenesis.[ADDRESS_1102612] milk after drug administration.   
5.1.2.  CPP -1X (Eflornithine ) Pharmacokinetics  
The dose of CPP-1X (daily oral dose of 750 mg for an adult) for CPP -310 was selected based 
upon its known pharmacology and evidence from clinical studies.  
Time to peak concentration for oral eflornithine is 4 -6 hours.   
Absorption: for the oral solution is 54 -58% and is unaffected by [CONTACT_433438].   
Distribution: no protein binding sites , crosses blood -brain barrier, v olume of distr ibution is 0.3 -
0.35 liters/kg.  
Metabolism: urinary recovery of unchanged drug as eflornithi ne is 86% an d essentially not 
metabolized.  
Excretion: renal excretion.  Elimination half -life: 3 -3.5 hours but once daily oral dosing of 500-
750 mg is sufficient to maintain efficacy as indicated in several clinical trials.  
Eflornithine pharmacokinetic refe rences include, Abeloff, et al.,  1984 ,76 Haegele et al., 1981,77 
Meyskens, et al., 1998,35 and Meyskens et al., 2008 .41 
5.2. Sulindac  
Sulindac is a non -steroidal, anti -inflammatory indene derivative designated chemically as (Z) -5-
fluoro -2-methyl -1- [[p- (methylsulfinyl)phenyl]methylene] -1H-indene -3-acetic acid.  It is not a 
salicylate, pyrazolone or propi[INVESTIGATOR_480400].  Sulindac, a yellow crystalline compound, is a 
weak organic acid practically insoluble in water below pH 4.5, but very soluble as the sodium salt 
or in buffers of pH 6 or higher.    Sulindac 
tablets (USP) 150 mg tablets are round yellow tablets imprinted DAN and 5661 and are supplied 
in bottles of 100.  Dispense in a well -closed container with child -resistant closure.   
  
Sulindac is marketed in the US for relief of signs and symptoms of the following conditions:  
osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful  shoulder 
(bursitis/tendinitis), and acute gouty arthritis.  

IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  29 Pregnancy and Lactation:  Pregnancy Category C. Sulindac crosses the placenta.  There have been 
no reports of congenital abnorma lities caused by [CONTACT_799373] o f sulindac.  However, sulindac 
should be avoided in late pregnancy because of the effects of p rostaglandin inhibition (closure of 
the ductus arteriousus) on the f etal cardiovascular system.  It  is not known whether this drug is 
excreted in human milk; however, it is secreted in the milk of lactating rats.  Because many drugs are excreted in human milk and because of the potential for ser ious adverse reactions in nursing 
infants from sulindac, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the  mother.  Refer to the Sulindac 
product insert (Actavis, formerly Watson Laboratories, Inc.)
[ADDRESS_1102613] insert (Actavis, formerly Watson Laboratories, Inc.)78 for additional 
information. 
Absorption:  90% bioavailability; sulindac must be metabolized to the sulfide metabolite before it 
is pharmacologically active. Distribution: Sulindac and its sulfone and sulfide metabolites are 93.1, 95.4 and 97.9% bound to 
plasma proteins.  Sulindac penetr ates the blood-brain barrier and placental barriers. 
Metabolism: Sulindac and its sul fone metabolite undergo extensive enterohepatic circulation 
relative to the sulfide metabolite in animals.  
Kinetics:  T
max for sulindac (150 mg tablet) i s 3.9 ± 2.3 hours, and 5.85±4.5 hours for the sulfone 
metabolite and 6.2 ± 3.1 hours for the sulfide metabolite. 
Elimination: Approximately 50% of the administered dose of suli ndac is excreted in the urine 
with the conjugated sulfone met abolite accounting for the major portion.  Less than 1% of the 
administered dose of sulindac a ppears in the urine as the sulfi de metabolite.  Approximately 25% 
is found in the feces, primarily as the sulfone and sulfide metabolites.  The mean effective half-
life (T 1/2) for sulindac is 7.8 hours and 16.4 hours for the active sulfi de metabolite. 
 
  
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102614] RECRUITMENT, INCLUSION AND EXCLUSION CRITERIA 
Subjects (male and female), ≥ 18 years will be recruited who me et the inclusion criteria below.  
Women and minorities will be represented according to their dis tribution in the Investigator’s 
clinical population. 
 Patient Characteristics for Eligibility, Inclusion Criteria 
1. Diagnosis of phenotypic classical FAP with disease involvement of the duodenum and/or 
colon/rectum/pouch. 
a) Genotype: APC mutation (with or without family history) require d  
b) Classical FAP Phenotype: 100’s to 1,000’s of colorectal adenoma tous polyps, usually 
appearing in teenage years 
2. UGI endoscopy/LGI endoscopy (proctoscopy/colonoscopy) performed  within [ADDRESS_1102615] colon/ rectum and prophylactic surgery is being considered as a 
stratification site. 
4. Rectal/pouch polyposis as a stratification site as follows: 
4.a  At least three years since colectomy with IRA/proctocolect omy with pouch, and 
demonstrating polyposis as defined by [CONTACT_37325] 1, 2, 3, of the proposed InSiGHT 2011 
Staging System (Appendix B ) and summarized as follows: 
Stage 1:  10-25 polyps, all < 5 mm 
Stage 2:  10-[ADDRESS_1102616] one > 1 cm 
Stage 3:  >25 polyps amenable to complete removal, or any incompletely removed sessile 
polyp, or any prior evidence of high grade dysplasia, even if c ompletely 
removed. [Note: For staging purposes only.] 
4.b  For all subjects, any rectal/pouch polyps > [ADDRESS_1102617] be excis ed at “baseline”. 
5. Duodenal polyposis as a stratifica tion site; one or more of the following: 
5.a  Current Spi[INVESTIGATOR_799302] 3 or 4. (Refer to Appendix A for M odified Spi[INVESTIGATOR_799303]). 
5.b  Prior surgical endoscopic in tervention within the past six months for Spi[INVESTIGATOR_799302] [ADDRESS_1102618] been down staged to Spi[INVESTIGATOR_350126] 1 or 2. 
6. Hematopoietic Status (within 30 days prior to randomization) : 
a) No significant hematologic abnormalities 
b) WBC at least 3,000/mm3  
c) Platelet count at least 100,000/mm3 
d) Hemoglobin at least 10.0 g/dL 
e) No history of clinical coagulopathy 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  31 7. Hepatic Status (within 30 da ys prior to randomization): 
a) Bilirubin no greater than 1.[ADDRESS_1102619] 
b) AST and ALT no greater than 1.[ADDRESS_1102620] 
c) Alkaline phosphatase n o greater than 1.[ADDRESS_1102621] 
8. Renal Status (within 30 days prior to randomization): 
a) Creatinine no great er than 1.[ADDRESS_1102622] 
9. Hearing: 
a) No clinically significant hearing loss, defined in Section [ADDRESS_1102623] use 
effective contraception*.  C onfirmation of postmenopausal statu s unless surgically sterile**. 
12. Absence of gross blood in stool ; red blood on toilet paper only  acceptable.  
13. No discrete gastric or duodenal  ulcer greater than [ADDRESS_1102624] 5 years except resected non-melanomatous skin 
cancer, papi[INVESTIGATOR_6686] , or precancerous cervical dysp lasia. 
15. No other significant medical or psychiatric problems that would  preclude study participation 
or interfere with capacit y to give informed consent. 
16. Use of 81 to 100 mg daily aspir in or up to 700 mg aspi[INVESTIGATOR_702966] a week are 
eligible. 
17. No concurrent warfarin, fluconazole, lithium, Pradaxa® or other direct thrombin inhibitors, 
Plavix®, cyclosporine, other NSAIDs (such as ibuprofen, aspi[INVESTIGATOR_799304] s of 700 mg weekly, 
diflunisal), diuretics (furosemid e and thiazides), DMSO, methotrexate, probenecid, 
propoxyphene hydrochloride, Tylenol® (acetaminophen) preparations containing aspi[INVESTIGATOR_799305]. 
18. Willingness to forego concurrent use of supplements containing omega-3 fatty acids, oral 
corticosteroids, non-steroidal an ti-inflammatory drugs or other  FAP directed drug therapy. 
19. Able to provide written informed  consent and follo w protocol requirements. 
*Fertile male or female, effectiv e contraception methods includ e the established use of o ral, injected or implanted 
hormonal methods of contraception, placement of an intrauterine  device (IUD) or intrauterine system (IUS), barrier 
methods of contraception: condom or occlusive cap (diaphragm or  cervical/vault caps) with spermicidal 
foam/gel/film/cream/suppository , male sterilization (with the appropriate post-vasectomy documentation of the 
absence of sperm in the ejacula te), or true abstinence, when th is is in line with the prefe rred and usual lifestyle of 
the subject.  Periodic abstinen ce (calendar, ovulation, symptot hermal, post-ovulation methods) and withdrawal are 
not acceptable methods of contr aception.  Contraceptives should  be used during the study and for at least 2 weeks 
after study treatment.  
Male subjects (including men who have had vasectomies) whose pa rtners are pregnant should use condoms while 
the partner is pregnant. If the partner is still pregnant when the subject goes off study, the subject should continue 
condom uses for at leas t 2 weeks afterwards. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  32 **Postmenopausal status may be confirmed by [CONTACT_799374] g: a) ≥ 12 months spontaneous amenorrhea; b) 6 
months spontaneous amenorrhea w ith serum FSA levels > 30 IU/L79,80; c) ≥ 6 weeks postsurgical bilateral 
oophorectomy; d) ≥ [ADDRESS_1102625] eroids within 30 days of enrol lment. 
3. Treatment with other investigational agents in the prior 4 week s. 
4. Use of other non-steroidal anti-i nflammatory drugs (such as ibuprofen) exceeding 4 days 
per month, in the prior 6 weeks. 
5. Regular use of aspi[INVESTIGATOR_799306] 700 mg per week. 
6. Treatment with other FAP directe d drug therapy (including sulin dac or celecoxib, fish oil) 
within 12 weeks of study enrollment. 
7. Hypersensitivity to cyclooxygena se-2 inhibitors, sulfonamides, NSAIDs, or salicylates; 
NSAID associated symptoms of gastritis. 
8. Patients must not have cardiovascular disease risk factors as defined below.  
• Uncontrolled high blood pressure  (systolic blood pressure > 150  mm Hg; 
• Unstable angina;  
• History of documented myocardial  infarction or cerebrovascular accident; 
• [LOCATION_001] Heart Association Class III or IV heart failure (Refer  to Appendix C); 
• Known uncontrolled hyperlipi[INVESTIGATOR_258604]-C ≥ 190 mg/dL or triglycerides ≥ 
500 mg/dL. 
9. Patients with significant hearing loss are not eligible for stu dy participation as defined 
below. 
• Hearing loss that affects everyday life and/or for which a hearing aid is required. 
10. Intact colon/rectum or retained rectum or ileal pouch:  
a) cancer on biopsy 
b) high grade dysplasia found on polyp biopsy where the polyp is n ot completely 
removed 
c) a large polyp (>1 cm) not completely removed. 
11. Duodenal cancer on biopsy. 
12. Intra-abdominal desmoid disease,  stage III or IV (staging crite ria in Appendix D).9,81 
13. Inability to provide informed consent. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102626] a screen failure case report form completed by [CONTACT_799375] . 
 
7. RANDOMIZATION AND STRATIFICATION 
Subjects eligible for this trial will be randomized into one of  three treatment groups 1:1:1 (CPP-
1X plus sulindac: CPP-1X placebo plus sulindac: CPP-1X plus sulindac placebo) and stratified by 
[CONTACT_799376]-related event prognosis using an interactive web-based system as described below.  Subjects will be randomized no more than [ADDRESS_1102627]-event prognosis.  The e vent prognosis groups are repre sented by 1) best (i.e., longest 
projected time to first FAP-rela ted event) - rectal/pouch polyp osis, 2) intermediate - duodenal 
polyposis and 3) worst - pre-colectomy.  If a subject has two o r more of these disease sites, the 
most severe prognosis stratum will be assigned for randomizatio n (e.g. worst > intermediate > 
best).  Since an individual may have more than one disease site  involved, the trial will assess the 
time from the date of randomizati on to the date of the first occurrence of any FAP-related event in 
the subject as a whole.  In order to minimize po tential treatme nt arm imbalance a centralized 
randomization process will be used to balance among treatment g roups within prognostic strata. 
 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102628] Assessments and Treatment Schedule 
The clinical study schedule/schem a (Table 3) provides the sched ule for screening, on-st udy visits and follow-up. 
Table 3 - FAP Study Schedule (Initial 24 Months of Treatment) 
 Screening 
/Baseline Mo. 
0-1-2 Mo. 
 3 Mo.  
4-5 Mo. 
 6 Mo.  
7 -8 Mo.  
9 Mo.  
10-11 Mo.  
12 Mo. 
13-14 Mo. 
15 Mo. 
16-17 Mo.  
18 Mo. 
19-20 Mo. 
21 Mo. 
22-23 24 mo. 
/EOT FU 30 days 
Off-Study  FU Mo. 2-6  
Off Study 
Procedures 
  ( ±  1  w k )  (± 2 wks) (± 1 wk) (± 2 wks) (± 1 wk) (± 2 wks) (± 1 wk) ± 2 wks21 ( ± 1 wk) 
Informed Consent X     X26
Polyposis Histor y1 X     
Medical Histor y24 X  X  X X X XX14
GI Symptoms X  X  X X X XX14
Surgical Histor y X     X14X19
Concomitant 
Medications X X13 X X13 X X13 X13 X13 X X13 X13 X13 X X13 X13 X13 X X14  
Drug Compliance 
Review  X13 X X13 X X13 X13 X13 X X13 X13 X13 X X13 X13 X13 X   
Adverse Events  X13 X X13 XX13X13X13XX13X13X13 XX13X13X13XX14
Chemistry Panel2 X  X  X X X X
CBC3 X  X  X X X X
Urinalysis25 X  X  X X X X
Vital Si gns4 X  X  X X X X
Physical Exam/Review 
of Systems5 X  X  X    X    X    X   
Audiometr y6 X    X X
EKG22 X  X23  X X X X
Serum Pre g. Test7 X  X  XX7XX7 XX7X
Dispense Medications8  X8 X  X  X8  X  X8  X  X8     
Subject Diary9  X  X  X  X  X  X  X  X     
Food Frequency Questionnaire
15 X        X        X   
LGI Endoscopy10 X    X    X    X    X   
Normal Mucosa Biopsy
11 X    X    X    X    X   
UGI Endosco py12 X    X X X X
Pharmacokinetics 
Blood Sam ples   X16                 
Pharmacogenomic Blood 
Sample X17                   
Polyamine Urine Samples
18 X    X    X    X    X   
HRQoL surveys 20 X  X  X    X    X    X   
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  35 FAP Study Schedule Footnotes (Table 3) 
Note: Shaded columns in subject schedule (Table 3) are protocol  required in person visits. 
1. Polyposis history: Fam ily history, age onset, physician or self -prescribed NSAIDs for polyp control, frequency and extent of p ost-colectomy interventions; specific 
findings during the past two endoscopi[INVESTIGATOR_014]. 
2. Chemistry panel includes – electrolytes (Na, K, CL, CO 2), liver function tests (AST, AL T, Alkaline phosphatase, biliru bin), BUN/urea, creatinine. 
3. CBC panel includes – hemoglobin, h ematocrit, WBC, platelet coun t, automated differential. 
4. Vital signs – temperature, blood pressure, pulse, respi[INVESTIGATOR_1520]. 
5. Physical Exam/Review of body sy stems (includes body system asse ssment - HEENT, hepatic, renal, genitourinary, reproductive, hematologic/immunologic, 
endocrine/metabolic, musculoskeletal, neurologic [i.e., grossly  normal, walk into offi ce, speech normal, no  tremors, alert and oriented], dermatologic, cardiovascular, 
respi[INVESTIGATOR_696], gastrointestinal) – including height (baseline onl y), weight, vital signs. 
6. Audiometry will need to be done using air conduction methodolog y (250, 500, 1000, 2000, 4000 and 8000 Hz). 
7. Women of child-bearing bearing potential with no prior hysterec tomy and pre-menopausal must use an effective contraception method and will have a serum pregnancy 
(HCG) done every 3 months while on study treatment (see Section  6.1, #11). 
8. Medications and subject diaries w ill be dispensed to the subjec t every 3 months (month 0, 3, 6, 9, 12, 15, 18, and 21) in pers on or by [CONTACT_799377]. 
9. Subjects are to record i n their 3-month diaries: medication use , presence of symptoms, and a sel f-assessment of presence of gr oss blood or melena. 
10. Lower GI (LGI) endoscopy (procto scopy or colonoscopy) will be d one on all randomized subjects th at have an intact colon or rec tum/pouch. 
11. During the LGI procedure, normal mucosal biopsy for polyamine a nalysis will be obtained at; sc reening/baseline, 6, 12, 18, and  24 months/EOT. For subjects with 
permanent ileostomy, endoscopy not required; normal mucosal bio psies are performed on the v isible ileostomy stoma.  
12. On-study Upper GI (UGI) endoscop y will be done on all randomize d subjects that have a duodenum. 
13. Monthly ( ± 7 days) phone/email contact [CONTACT_799378]-up on medication/drug compliance review, concomitant medication s, and adverse events. 
14. The follow-up will be done as pho ne call to the subject to revi ew medical history, surgical his tory for any FAP-related surgic al events, concomitant medications and 
adverse events. 
15. A food frequency recall questionn aire will be administered at t he screening/baseline, 12 and 24 month/EOT visits. US and Canad a sites only. 
16. A peripheral blood sample (5 mL, lithium heparin) will be colle cted at each of the following time points:  pre-dose and 1, 2, [ADDRESS_1102629] dose. 
17. A peripheral blood sample (10 m L, EDTA) will be collected at sc reening/baseline for pharmacogenomic analysis. 
18. A random urine sample (15 mL mi nimum) will be collected at the screening/baseline, 6, 12, 18 and 24 month/EOT visits for polya mine analysis. 
19. The follow-up will be done monthl y as phone call to review endo scopic excisional procedures/surgical history for any FAP-related surgical events. 
20. HRQoL surveys will include EORTC QLQ-C30 and QLQ- CR29, EQ-5D he alth utility index assessment, and modified Cancer Worry Scale.  They will be collected at 
screening/baseline, 3, 6, 12, 18, and 24 month/EOT visits. 
21. EOT visit will occur within [ADDRESS_1102630] needs to be in the supi[INVESTIGATOR_19636] 10 minutes prior to the EKG, including EKGs collected during PK sampling.  
23. 2-EKGs will be done on the day PK  samples are collected: 1) bef ore pre-dose sample and prior to dose, and 2) before the 4 hr P K sample is obtained.   
24. Medical history includes – standard review of major systems, wi th particular attention to cardiovascular, cerebrovascular, per ipheral vascular, gastrointestinal and 
hearing issues. Interaction with  outside physicians should be d ocumented. 
25. Urinalysis panel includes – colo r, clarity/appearance, specific  gravity, pH, protein, glucose, ketones and blood. 
26. Subjects completing the initial [ADDRESS_1102631] s not participating in the extension study, this will be the en d of treatment visit. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  36 Table 4 - FAP Study Schedule (Treatment Extension to a Maximum of 48 Months) 
 
 
Mo. 
 2421 Mo. 
25, 26 Mo. 
27 Mo. 
28, 29 Mo. 
30 Mo. 
31, 32 Mo. 
33 Mo. 
34, 35 M 
36 Mo. 
37-38 Mo. 
39 Mo. 
40-41 Mo. 
42 Mo. 
43-44 Mo. 
45 Mo. 
46-47 Mo. 
48/EOT FU 30 
days 
Off-
Study 
Procedures   (± 1 wk) (± 2 wks) (± 1 wk) (± 2 wks) ± 1 wk (± 2 wks)  
(± 1 wk) 
 (± 2 wks17) ± [ADDRESS_1102632] Diary8 X   X   X   X   X  X  X   X     
Food Frequency 
Questionnaire14         X        X  
LGI Endoscopy9     X     X    X    X  
Normal Mucosa Biopsy10     X     X    X    X  
UGI Endoscopy11     X     X    X    X  
Polyamine Urine Samples15     X     X    X    X  
HRQoL surveys 16     X     X    X    X  
  
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  37 FAP Study Schedule Treatment Extension Footnotes (Table 4) 
Note: Shaded columns in subject schedule (Table 4) are protocol  required in person visits. 
1. Chemistry panel includes – electrolytes (Na, K, CL, CO 2), liver function tests (AST, A LT, Alkaline phosphatase, biliru bin), BUN, creatinine. 
2. CBC panel includes – hemoglobin, h ematocrit, WBC, platelet coun t, automated differential. 
3. Vital signs – temperature, blood pressure, pulse, respi[INVESTIGATOR_1520]. 
4. Physical Exam/Review of body sy stems (includes body system asse ssment - HEENT, hepatic, renal, genitourinary, reproductive, hematologic/immunologic, 
endocrine/metabolic, musculoskeletal, neurologic [i.e., grossly  normal, walk into offi ce, speech normal, no  tremors, alert and oriented], dermatologic, cardiovascular, 
respi[INVESTIGATOR_696], gastrointestinal) – including height (baseline onl y), weight, vital signs. 
5. Audiometry will need to be done using air conduction methodolog y (250, 500, 1000, 2000, 4000 and 8000 Hz). 
6. Women of child-bearing bearing potential with no prior hysterec tomy and pre-menopausal must use  an effective contraception met hod and will have a serum pregnancy 
(HCG) done every 3 months while on study treatment (see Section  6.1, #11). 
7. Medications and subject diaries w ill be dispensed to the subjec t every 3 months (month 24, 27, 30,33, 36, 39, 42, and 45) in p erson or by [CONTACT_799379]. 
8. Subjects are to record i n their 3-month diaries: medication use , presence of symptoms, and a sel f-assessment of presence of gr oss blood or melena. 
9. Lower GI (LGI) endoscopy (procto scopy or colonoscopy) will be d one on all randomized subjects th at have an intact colon or rec tum/pouch. 
10. During the LGI procedure, normal mucosal biopsy for polyamine a nalysis will be obtained at months 30, 36, 42 and 48/EOT visits . For subjects with permanent 
ileostomy, endoscopy not required ; normal mucosal biopsies are performed on the visible ileostomy stoma.  
11. On-study Upper GI (UGI) endoscop y will be done on all randomize d subjects that have a duodenum. 
12. Monthly ( ± 7 days) phone/email contact [CONTACT_799378]-up on medication/drug compliance review, concomitant medication s, and adverse events. 
13. The follow-up will be done as pho ne call to the subject to revi ew medical history, surgical his tory for any FAP-related surgic al events, concomitant medications and 
adverse events. 
14. A food frequency recall questionn aire will be administered at m onth 36 and 48/EOT visit. U S and Canada sites only. 
15. A random urine sample (15 mL mi nimum) will be collected at mont hs 24, 30, 36, 42 and 48/EOT visits for polyamine analysis. 
16. HRQoL surveys will include EORTC QLQ-C30 and QLQ- CR29, EQ-5D he alth utility index assessment, and modified Cancer Worry Scale.  They will be collected at 
months 30, 36, 42 and 48/EOT visits. 
17. EOT visit will occur within [ADDRESS_1102633] needs to be in the supi[INVESTIGATOR_19636] 10 minutes prior  to the EKG.  
19. Medical history includes – standard review of major systems, wi th particular attention to cardiovascular, cerebrovascular, per ipheral vascular, gastrointestinal and hearing 
issues. Interaction with outside physicians should be documente d. 
20. Urinalysis panel includes – colo r, clarity/appearance, specific  gravity, pH, protein, glucose, ketones and blood. 
21. These procedures are in addition to those listed for Month 24 o n the initial treatment s chedule (Table 3). 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  38 
 Patient Accrual Logistics 
 Initial Visit – Determinin g Potential Eligibility 
Based on general medical and polyp osis history, prior surgery, cardiac risk assessment and 
clinical hearing loss, current a spi[INVESTIGATOR_799307] - patients  will be determined to be 
potentially eligible for this tr ial.  After appropriate discuss ions, written informed consent will be 
obtained. 
 Subsequent Screening for Eligibility 
If the patient has not already b een genotyped for FAP, genetic analysis will be performed to 
confirm the presence of an APC mutation.  
Lower GI Endoscopy:  Patients wi ll be evaluated via colonoscopy , flexible or rigid procto-
sigmoidoscopy during the screening phase.  B iopsies, ablations, and snare excisions at baseline 
are performed per the clinician’s standard of care.  If conside red eligible based on inclusion 
criteria, a grossly normal mucosa biopsy will be obtained for b aseline polyamine measurement.  
Still and video documentation of the colon (vide infra) or the residual rectum or entire pouch will 
also be obtained for archiving.  Polyp size will be determined by [CONTACT_799380] 5.0 – [ADDRESS_1102634] colon or rectum/pouch will 
have baseline and on-study lower GI endoscopy procedures as par t of this trial. 
Upper GI Endoscopy:  The duodenum will be evaluated by [CONTACT_703008]-viewing and/or side-viewing 
gastroscopes (with still and video documentation with closed and open biopsy forceps near 
mucosa).  Procedural details are  provided in the Investigator M anual.  All randomized patients 
with a duodenum will have base line and on-study UGI endoscopy as part of this trial. Subjects 
stratified to the duodenal group must have duodenal biopsies of all polyps 1 cm or larger to determine HGD and histology requ ired for determining Stage 3 or  4 Spi[INVESTIGATOR_799308].  
A physical exam/review of body systems, height, weight and vita l signs will be performed. 
Baseline blood and urine tests within 30 days of randomization:  Per eligibility c riteria – CBC, 
chemistry profile, urinalysis, and a sample for pharmacogenomic  and genetic analysis. 
In order to ascertain how many patients with clinical FAP have baseline hearing deficits, patients 
meeting all the criteria for this trial will undergo air conduc tion audiometry.  Results will not be 
relevant to eligibility. 
 Final Eligibility and Potential Screen Failures 
If the patient has signed the informed consent, and all eligibi lity criteria are met, the subject will 
be randomized.  Screening UGI, LGI  and rectal/pouch images will  be submitted to the central 
imaging laboratory for central collection and archiving.  Quali ty of life questionnaires (EORTC 
QLQ-C30, EORTC QLQ-CR29, EQ-5D , and the modified Cancer Worry Scale) will be provided 
to the subject to complete to obtain baseline values.  A food f requency questionnaire will be 
provided to the subject to complet e for baseline values at Nort h American ([LOCATION_002] and 
Canada) sites only. 
The patient may be a screen failure based on history, physical exam, genetic assessment, or other 
laboratory values.  A screen failu re case report form will need  to be completed by [CONTACT_799381] t he study Sponsor.  
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  39 
 Drug Administration 
After confirming eligibility, th e patient will be randomized to  one of the three treatment arms 
(Table 5).  Randomization should be performed within 5 working days prior to the initiation of 
treatment.  Specific procedures for randomization will be inclu ded in the study manual. 
Table 5 - Study Medication Schedule1 
AGENT and DOSE  ROUTE  RX INTERVAL  
CPP-1X 750 mg & Sulindac 150 mg  Oral Daily for up to 48 
months  
OR  
CPP-1X placebo  & Sulindac 150 mg  Oral Daily for up to 48 
months  
OR  
CPP-1X 750 mg & Sulindac placebo  Oral Daily for up to 48 
months  
1The medications are to be taken  at approximately the same time daily with food. 
* Each CPP-1X tablet = 250 mg;  ** Each sulindac tablet = [ADDRESS_1102635] assessmen ts and the treatment schedule for 
screening, on-study, end of trea tment and follow-up visits. 
During the initial 24-month drug intervention, subjects will be followed monthly by [CONTACT_799382].  A diary of compliance and symptoms will be maintained by [CONTACT_799383].  At each interval assessm ent visit (month 3, 6, 12, 18, and 24), until the subject completes 
[ADDRESS_1102636] diaries will be provided. 
At months 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22,  23 (+ 1 week), a follow-up visit via 
phone contact [CONTACT_326878] t o assess for side effects, oth er medications, to remind subjects 
to complete their diary and to c ontinue to take their study med ications. 
At the 3-month visit (+ 1 week), subjects will have a physical exam/review of body systems 
(including weight and vital signs ), blood and urine samples obtained for laboratory tests (CBC, 
chemistry panel, urinalysis), pharmacokinetics (PK), and EKGs (before the pre-dose sample, 
prior to drug administration and before the 4-hour PK sample co llection.  Subject needs to be in 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  40 the supi[INVESTIGATOR_19636] 10 minut es prior to the EKG).  Women of child bearing potential will also 
have a serum pregnancy test pe rformed.  Concomitant medications , adverse events and 
medication compliance will also be reviewed.  Quality of life questionnaires (EORTC QLQ-C30, 
EORTC QLQ-CR29, EQ-5D, and the m odified Cancer Worry Scale) wil l be provided to the 
subject to complete. 
At the 6-month and 18-month visits (+ 2 weeks), subjects will h ave a physical exam/review of 
body systems (including weight a nd vital signs), blood samples obtained for laboratory tests 
(CBC, chemistry panel, urinalysis), a random urine sample will be obtained for polyamine 
determination, EKG (Subject need s to be in the supi[INVESTIGATOR_19636] 10 minutes prior to the EKG) 
and their first on study treatme nt upper and lower endoscopy pr ocedures with image and video 
documentation will be obtained.  A normal rectal/pouch mucosal biopsy for polyamine 
determination will be obtained during the colonoscopy/proctosco py procedure.  Women of child 
bearing potential will also have a serum pregnancy test perform ed. Concomitant medications, 
adverse events and medication compliance will also be reviewed.  Quality of life questionnaires 
(EORTC QLQ-C30, EORTC QLQ-CR29 , EQ-5D, and the modified Cancer Worry Scale) will 
be provided to the subject to complete. Study drug and diaries will be dispensed. 
At the 9-month, 15-month and 21-month visits (+ 1 week), subjec ts will have drug and diary 
dispensing. Women of child bearing potential will also have a s erum pregnancy test performed.  
Concomitant medications, adverse events and medication complian ce will also be reviewed. 
At the 12-month and 24-month vi sits (+ 2 weeks), subjects will have a physical exam/review of 
body systems (including, weight a nd vital signs), blood samples obtained for laboratory tests 
(CBC, chemistry panel, urinalysis), a random urine sample will be obtained for polyamine 
determination, audiometry testing, EKG (Subject needs to be in the supi[INVESTIGATOR_19636] 10 
minutes prior to the EKG) and their second set of on study trea tment endoscopy procedures with 
image and video documentation will be obtained. A normal mucosal biopsy for polyamine 
determination will be obtained during the colonoscopy/proctosco py procedure.  Women of child 
bearing potential will also have a serum pregnancy test perform ed. Concomitant medications, 
adverse events and medication compliance will also be reviewed.  Quality of life questionnaires 
(EORTC QLQ-C30, EORTC QLQ-CR29 , EQ-5D, and the modified Cancer Worry Scale) will 
be provided to the subject to complete.  A food frequency quest ionnaire will be provided to the 
subject to complete at North Ame rican ([LOCATION_002] and Canada) sites only. Study drug and 
diaries will be dispensed at 12- month and if the subject contin ues on the treatment extension at 
24-month. 
Subjects completing the initial [ADDRESS_1102637] completed the 24 month visit procedures as outlined below may be eligible to participate in 
the 24 month treatmen t extension (See Section 8.2.10).  For tho se subjects that do not go on to 
the treatment extension, this wil l be the end of treatment visit.  It must be documented in the 
subject’s medical record why the subject declined participation  in the treatment extension if they 
met the requirements for participation, see Section 8.2.10. 
 Initial 24 Month Treatment Interv ention Early Termination (+ 2 weeks) 
Within [ADDRESS_1102638] a follow-up 
history and physical exam/review of body systems (including, we ight and vital signs), along with 
toxicity assessment.  Repeat bl ood laboratory tests (CBC, chemistry panel, and urinalysis), a 
random urine sample will be obtai ned for polyamine determinatio n, EKG (Subject needs to be in 
the supi[INVESTIGATOR_19636] 10 minutes prior to the EKG) and audiom etry will be performed.  Women 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102639] a serum pregnancy tes t performed.  Concomitant 
medications, adverse events and medication compliance will also  be reviewed.  Quality of life 
questionnaires (EORTC QLQ-C30, E ORTC QLQ-CR29, EQ-5D and the mo dified Cancer 
Worry Scale) will be provided to  the subject to complete.  A fo od frequency questionnaire will 
be provided to the subject to co mplete at North American (Unite d States and Canada) sites only.  
Repeat upper and lower endoscopi[INVESTIGATOR_799309] 24/EOT visit or if the subject has completed at least 3 m onths of treatment from the 
previous on-study upper and lower endoscopy procedures (includi ng baseline).  A normal 
mucosal biopsy sample for polyamine determination will be obtained during the 
colonoscopy/proctoscopy procedure. 
If the subject has an unscheduled upper/lower endoscopy for any reason, these procedures should 
be captured with image and video documentation including the co llection of a normal mucosal 
biopsy, if possible.  A random uri ne sample should be obtained for polyamine determination, if 
possible. 
Subjects will be formally taken off-study treatment and complet e the End of Treatment (EOT) 
assessments if there is a cumu lative delay/suspension of study medication for any reason of: 
 > 90 days from randomization to month 36 
 > 105 days from randomization to month 42 
 > 120 days from randomization to month 48 
A temporary suspension from taking study medication as stated a bove (for example, due to a 
non-FAP disease related surgery or procedure), will be documented as a treatment delay and the 
subject will continue on study, on their original schedule. 
 Initial 24 Month Treatment Interv ention Follow-Up (30-days post  end of treatment 
visit +/- 1 week) Off Study 
Thirty-days (30) after completi on of the end of study evaluations, subjects will be contact[CONTACT_799384] a clinical update in reg ard to symptoms and interval medical history.  Concomitant 
medications and adverse events will also be reviewed.  The subject will provide a clinical update and procedure date for any FAP-related surgical event or major endoscopic excisional event that 
has occurred since the last contact. These include partial cole ctomy, colectomy with IRA, total 
procto-colectomy, proctectomy, pouch resection, sub-mucosal res ection, trans-duodenal 
excision, ampullectomy, duodenect omy, or Whipple procedure. 
An FAP-related event at any dis ease site (colon/rectum/pouch, d uodenum) will lead to 
discontinuation of the study treatment but follow-up of the sub ject will continue until the end of 
the 30 day follow-up period. 
 Initial 24 Month Treatment Intervention Follow-Up (Months 2-6, each month +/- 1 
week) Off Study 
For the next 5 months after the 30 day follow-up, if the subjec t went off study treatment for 
disease progression indicating th e need for an any FAP-related surgical event or major 
endoscopic excisional event, and the surgical/en doscopic event had not yet occurred at the time 
of the [ADDRESS_1102640].  T hese include partial colecto my, colectomy with IRA, total 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102641] omy, or Whipple procedure. 
 Treatment Extension Intervention (Months 25 - 48) 
Subjects completing the initial [ADDRESS_1102642] meet the following requirements: 
1. Subject has completed [ADDRESS_1102643] drug  and diary dispensed. 
At months 25, 26, 28, 29, 31, 32, 34, 35, 37, 38, 40, 41, 43, 4 4, 46, and 47 (+ 1 week), a follow-
up visit via phone contact [CONTACT_799385], other medications, to remind subjects to 
complete their diary and to cont inue to take their study medica tions. 
At the 27-month, 33-month, 39-mo nth and 45-month visits (+ 1 we ek), subjects will have drug 
and diary dispensing. Women of child bearing potential will als o have a serum pregnancy test 
performed.  Concomitant medicatio ns, adverse events and medicat ion compliance will also be 
reviewed. 
At the 30-month and 42-month vi sits (+ 2 weeks), subjects will have a physical exam/review of 
body systems (including weight a nd vital signs), blood samples obtained for laboratory tests 
(CBC, chemistry panel, urinalysis), a random urine sample will be obtained for polyamine 
determination, EKG (Subject need s to be in the supi[INVESTIGATOR_19636] 10 minutes prior to the EKG) 
and their first on study treatme nt upper and lower endoscopy pr ocedures.  A normal rectal/pouch 
mucosal biopsy for polyamine d etermination will be obtained during the 
colonoscopy/proctoscopy procedure.  Women of child bearing potential will also have a serum 
pregnancy test performed. Concomitant medications, adverse even ts and medication compliance 
will also be reviewed. Quality of life questionnaires (EORTC QL Q-C30, EORTC QLQ-CR29, 
EQ-5D, and the modified Cancer Worry Scale) will be provided to  the subject to complete. 
At the 36-month, and 48-month vi sits (+ 2 weeks), subjects will have a physical exam/review of 
body systems (including, weight a nd vital signs), blood samples obtained for laboratory tests 
(CBC, chemistry panel, urinalysis), a random urine sample will be obtained for polyamine 
determination, audiometry testing, EKG (Subject needs to be in the supi[INVESTIGATOR_19636] 10 
minutes prior to the EKG) and their second set of on study treatment endoscopy procedures. A normal mucosal biopsy for polyamine determination will be obtained during the colonoscopy/proctoscopy procedur e.  Study drug and diaries will  be dispensed at 36-month if 
eligible to continue. Women of child bearing potential will als o have a serum pregnancy test 
performed. Concomitant medicatio ns, adverse events and medication compliance will also be 
reviewed. Quality of life questi onnaires (EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and 
the modified Cancer Worry Scale) w ill be provided to the subjec t to complete.  A food frequency 
questionnaire will be provided to the subject to complete at North American ([LOCATION_002] and Canada) sites only. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  43 
 Treatment Extension - End of Treatment/Early Termination (+/- 2  weeks) 
Within [ADDRESS_1102644] a follow-up 
history and physical exam/review of body systems (including, we ight and vital signs), along with 
toxicity assessment.  Repeat bl ood laboratory tests (CBC, chemistry panel, and urinalysis), EKG 
(Subject needs to be in the supi[INVESTIGATOR_19636] 10 minutes prio r to the EKG) and audiometry will 
be performed. Women of child bearing potential will also have a  serum pregnancy test 
performed. Concomitant medicatio ns, adverse events and medication compliance will also be 
reviewed. Quality of life questi onnaires (EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D and 
the modified Cancer Worry Scale) w ill be provided to the subjec t to complete.  A food frequency 
questionnaire will be provided to the subject to complete at North American ([LOCATION_002] and 
Canada) sites only.  
Repeat upper and lower endoscopi[INVESTIGATOR_799310] 3 months of treatment from the 
previous on-study upper and lower endoscopy procedures (includi ng month-24). A normal 
mucosal biopsy will be obtained during the colonoscopy/proctosc opy procedure and a urine 
sample will be collected for polyamine determination. 
If the subject has an unscheduled upper/lower endoscopy for any reason, these procedures should 
be captured with image and video documentation including the co llection of a normal mucosal 
biopsy, if possible.  A random uri ne sample should be obtained for polyamine determination, if 
possible. 
 Treatment Extension Follow-Up (30-days post end of treatment visit +/- 1 week) 
Off Study 
Thirty-days (30) after completi on of the treatment extension ev aluations, subjects will be 
contact[CONTACT_8344] a clinical  update in regard to symptoms and interval medical history.  
Concomitant medications and adverse events will also be reviewe d. The subject will provide a 
clinical update and procedure date for any FAP-related surgical event or major endoscopic excisional event that has occurred since the last contact. These include partial colectomy, colectomy with IRA, total procto-colectomy, proctectomy, pouch resection, sub-mucosal 
resection, trans-duodenal excisi on, ampullectomy, duodenectomy,  or Whipple procedure. 
An FAP-related event at any dis ease site (colon/rectum/pouch, d uodenum) will lead to 
discontinuation of the study treatment but follow-up of the sub ject will continue until the end of 
the 30 day follow-up period. 
 Termination of Treatment Extension Procedures 
Subjects on the treatment extensi on can continue on treatment for up to 48 months based on their 
date of randomization as follows: 
1. If randomized between November 2015 and April 2016 eligible for  up to 36 months 
2. If randomized between May 2015 a nd October 2015 eligible for up  to 42 months 
3. If randomized between July 2014 and April 2015 eligible for up to 48 months 
or until one of the following occurs: 
1. Subject has an FAP-related event or comes off study for other r easons 
2. Trial end-date of April 30, 2019 has been reached 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102645] accrued prior to April 30,  2019 and an earlier trial 
end-date has been set by [CONTACT_799386] 
5. An earlier trial end date prior to April 30, 2019 has been reco mmended by [CONTACT_799387]. 
 Treatment Compliance 
Subjects will be formally taken off-study treatment and complet e the End of Treatment (EOT) 
assessments if there is a cumu lative delay/suspension of study medication for any reason of: 
 > 90 days from randomization to month 36 
 > 105 days from randomization to month 42 
 > 120 days from randomization to month 48  
 Definition of FAP-Related Events or Serious and Unexpected Toxicity 
The time from the date  of randomization to the date of the firs t occurrence of any FAP-related 
event at any disease site (col on/rectum/pouch, duodenum) will lead to discontinuation of the 
study treatment.  Follow-up of the subject for FAP-related even ts will continue, per protocol, 
until the end of the [ADDRESS_1102646]-treatment. 
FAP-related primary events by [CONTACT_799388]: 
1. Pre-operative, intact colon: 
a) Disease progression^ indicating need for colectomy with IRA or total procto-
colectomy  
 
2. Rectum or pouch events include one or more of the following: 
a) Excisional intervention by [CONTACT_799389]-anal excisio n to remove any 
polyp ≥ 10 mm in size (per patholo gy report) and/or pathologic evidence of high 
grade dysplasia.* 
b) Disease progression^ indicat ing need for proctectomy 
c) Disease progression^ indicati ng need for pouch resection 
d) Development of cancer in rectum or pouch 
e) Death 
 
3. Duodenal disease includes the following: 
a) Progression in Spi[INVESTIGATOR_799311] (Stage 2,  3 or 4), refer to 
Appendix A 
b) Disease progression indicating need for excisional intervention  (sub-mucosal 
resection, trans-duodenal excisi on, ampullectomy, duodenectomy,  Whipple 
procedure) 
c) Development of cancer 
d) Death 
 
Note, excisional intervention ma y include open surgery, trans-a nal surgery or endoscopic 
excisions/snare but does not include cautery ablations or hot b iopsy. 
*For those subjects stratified to  the duodenal group, all concu rrent rectal pouch polyps > [ADDRESS_1102647] been removed at baseline for this event to apply. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  45 ^Disease progression is based on endoscopic evaluations compared to baseline demonstrating a 
clinically significant increase in number and/or size of polyps (~25% increase in disease burden), 
presence of a large sessile or ulcerated adenoma not amenable t o removal, high grade dysplasia 
in any adenoma, or in-situ or invasive cancer. 
Discontinuation from study treatm ent due to a potential treatment related serious adverse event 
may include the following:  
• Gastrointestinal hemorrhage, ≥ grade 3 
• Tinnitus ≥ grade 2, or clinical hearing impairment ≥ grade 3 
• Cardiovascular events include cardiac arrest, cardiac-chest pai n, myocardial 
infarction, thromboembolic event, phlebitis (deep or superficial), and spontaneous 
abdominal wall or retroperiton eal hematoma at least 10 cm in ma ximum dimension.  
• Grade ≥ 3 Cardiac ischemia/infarc tion or cerebrovascular ischem ia, whether related 
to study drug or not. 
Adverse events and serious adverse events must be recorded care fully and completely on the 
case report forms and SAE report forms.  Adverse event reportin g and grading will be done 
using the NCI Common Terminology Criteria for Adverse Events (C TCAE), Version 4.03. 
If a subject comes off study trea tment for any of the above lis ted FAP or SAE events, the subject 
will need to complete all tests, procedures and assessments required at the Final Intervention/End of Treatment visit, including 30-day follow-up. 
All subjects who go off study treatment due to an FAP-related e vent, toxicity, or intercurrent 
illness, or who withdraw consent for further treatment will be followed for at least [ADDRESS_1102648]’s treatment 
assignment may occur if in the op inion of the Investigator that the identification of the study 
medication is necessary to protec t the welfare of the subject. The study drug may be discontinued 
without unblinding the participant. 
If the blind is prematurely broken for a subject, it is the res ponsibility of the Investigator to 
promptly document and explain any unblinding to Cancer Preventi on Pharmaceuticals within [ADDRESS_1102649] treatment i s done via the IWRS by [CONTACT_14520].  If the Investigator is 
unable to access IWRS, the Drug Safety Group at Chiltern should be contact[CONTACT_6811] 1-919-468-
2288 (US) and 001-[PHONE_16695] (EU) for  a subject’s treatment c ode. 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102650] awal (Off-Study Treatment) 
Participants will be withdrawn from protocol treatment under th e following circumstances: 
1. Evidence of an FAP-related event as defined in Section 8.2.14.  
2. Clinical reduction in hearing ac umen requiring use of a hearing aid. 
3. Grade ≥ 3 cardiac ischemia/infarc tion or cerebrovascular ischem ia, whether related to 
study drug or not. 
4. Pregnancy while on treatment, see Section 11.8. 
5. Intercurrent illness which would, in the judgment of the treati ng physician, affect 
assessments of clinical status to a significant degree and/or r equire discontinuation of 
drugs.  Participants will not discontinue study drugs for other medical events which are 
not considered to be treatment related.  This determination wil l be made by [CONTACT_30780].  
6. Cumulative delay of study intervention for any reason as follow : 
• > 90 days from randomization to month 36 
• > 105 days from randomization to month 42 or 
• > [ADDRESS_1102651] day of study treatmen t initiation is t he randomizatio n date regardless of study 
visit and/or procedure delays. 
7. Completion of treatment intervention. 
8. At the request of the Sponsor in situations such as protocol violations or concerns about the subject’s safety. 
9. The subject is lost to follow-up. 
10. The subject may withdraw from the study-treatment at any time for any reason. 
11. Subject death. 
 Protocol Withdrawal (Off-Study) 
1. The subject may withdraw from the study at any time for any reason. 
9. DISEASE ASSESSMENT AND SAMPLE COLLECTION 
 Baseline Endoscopy 
A. Colon, Rectal, Pouch Assessment 
Colonoscopy or flexible sigmoidoscopy will be used to assess th e colon, rectum or the neo-rectum 
(ileal pouch) and video images captured for archiving and subse quent review.  The last images 
will be retroflexed pi[INVESTIGATOR_799312] t he anorectal ring.  One pass will be 
performed.  Further details will be provided in the Imaging Manual. 
Rectal/Neorectal Pouch 
The entire residual rectum or pouch will be video-captured thre e times by: 
 Advancing flexible scope to ileo-rectal anastomosis or proximal  pouch.  After 
advancement, the scope will be “twirled” to visualize all walls  of the bowel as it is 
withdrawn. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  47  Retroflexed views of the distal rectum will be obtained at each  visualization. 
 Images of the bowel will be obtai ned using biopsy forceps in th e fully open position 
placed near the mucosa. 
Rectal/Neorectal Pouch Enumeration and Measurement 
 Number of polyps in the rectum or pouch 
 Endoscopic estimation of polyp size will be determined by [CONTACT_661209] l comparison to a biopsy 
forceps that can measure, 5.0 - 5.5mm in the fully open positio n. 
o Number of polyps between 5 – 10 mm 
o Number of polyps > 10 mm 
 All rectal/pouch polyps > [ADDRESS_1102652] will 
be stratified to the rectum/pouc h group.  For details concerning subjects stratified to the 
rectal/pouch polyposis group (with  or without involvement of th e duodenum) please see 
Section 6.1, #4.  For details concerning subjects stratified to  the duodenal polyposis group 
(with or without involvement of re ctum/pouch at stratification) please see Section 8.2.14.  
Smaller polyps may be ablated per the treating institutions standard of care and three additional 
sets of video images will then be obtained as “baseline”.  
B. Duodenal Assessment Duodenal assessment will use a fo rward and/or side-viewing endo scope with video images 
captured for subsequent review .  The Spi[INVESTIGATOR_799313] (Appendix A) at screening will be 
utilized to stage the initial extent of disease and assess subj ect eligibility.  A side-viewing scope 
may be used to improve assessment of the ampulla of Vater/papil la.  Ampullary biopsies (with 
histology) and snare excisions will be performed per the protoc ol, Investigator Manual, and the 
institution’s standard of care and the results of these procedures will be used as the subject’s 
baseline Spi[INVESTIGATOR_799313].  Further details will be pro vided in the Imaging Manual. 
The screening stage will be the initial Spi[INVESTIGATOR_799302] (extent  of polyposis combined with 
histology) and the baseline  Spi[INVESTIGATOR_799314]-snare intervention. 
 Follow-up Endoscopi[INVESTIGATOR_799315] (+/- two weeks) – per Section 8.1, subje cts will undergo repeat upper and 
lower endoscopy.  At any interval assessment, if any subject requires an excisional intervention (as defined in Section 8.2.14), or has duodenal Spi[INVESTIGATOR_799316] (Stage 2, 3 or 4), the subject will be considered to have an FAP-related event and wil l come off study treatment.  
 Imaging Submission 
All de-identified images will be captured on DVD or flash drive, de-identified, and forwarded to a central imaging laboratory for archiving.  All data will be d e-identified in regard to subject, site 
and treatment but subject study ID number will be available for baseline and subsequent 
comparison as appropriate.  Post-ho c global assessment by [CONTACT_799390] t - using a 5 point scale - muc h less, somewhat less, none or 
minor changes, somewhat worse, much worse.  This process will b e defined in detail and 
included in the imaging manual fo r still and video endoscopy im age submission. 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102653] blood samples obtained for pharmacokinet ic studies.  Pharmacokinetic 
sampling will occur once at the s cheduled 3-month visit.  Samples may be collected within ± [ADDRESS_1102654] t hree (3) days prior to the scheduled 
visit to remind the subject to n ot take their morning dose of s tudy medication on the day of the 
planned visit. 
On the morning of the visit, upon subject arrival, it will be v erified that the subject did not take 
their morning dose of study medi cation.  Those subjects that mistakenly took their morning dose 
will be sent home and rescheduled within the next week.   Prior to the pre-dose blood sample collection, a resting EKG wi ll be obtained (subject needs to 
be in the supi[INVESTIGATOR_19636] 10 minutes prior to the EKG).  After the EKG was obtained, a pre-
dose blood sample (5 mL, lithium heparin vacutainer tube) will be collected.   
The subject will then take their study medications in the usual  manner.  The subject may then 
leave the clinic and have their typi[INVESTIGATOR_619980].  Subjects wi ll be asked to note the time breakfast 
was finished, as that will be recorded. Table 6 – Pharmacokinetic Sample Number, Sampling Times and EKG  collection 
Sample 
Number Target Time No Earlier Than  No Later Than  
 EKG – Prior to pre-dose sample collection and drug administration  
1 Pre-dose * N A N A
[ADDRESS_1102655] dose 90 minutes 150 minutes 
 EKG – Prior to [ADDRESS_1102656] dose* [ADDRESS_1102657] dose 6 hours 10 hours 
*EKGs need to be done  1) before the pre-dose sample and before drug administration 
and 2) before  the [ADDRESS_1102658] dose blood samples will be collected (5 mL each) at 1, 2, 4, and 8 hours following the 
morning dose of study medication (see Table 5).  Deviations aro und these sample times should 
be no more than ± 15 minutes, ± 30 minutes, ± 60 minutes (1 hou r), ± 120 minutes (2 hours), 
respectively, keepi[INVESTIGATOR_799317].   
At the 4 hour time point and prior to the 4 hour blood sample collection, a resting EKG will be 
obtained (subject needs to be in the supi[INVESTIGATOR_19636] 10 min utes prior to the EKG).  After the 
EKG is obtained, the 4 hour time point blood sample (5 mL, lith ium heparin vacutainer tube) 
will be collected. On the pharmacokinetic sampling ca se report form page, study co ordinators will record the time 
of the pre-dose blood sample and the time breakfast was finished.  Also, the relative ideal blood 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  49 sampling times (relative to dose time), and the actual blood sampling times will be recorded.  
Missed samples or samples collect ed outside of th e time windows will still be stored and 
analyzed.  Collected blood samples will be processed, stored, a nd shipped to a central laboratory 
according to procedures provided in the study manual. 
Plasma concentration data from this trial will be pooled with d ata from other clinical trials, when 
available, for analysis.  For each drug, a database will be con structed that includes the nominal 
and recorded dosing history, plasma analyte concentrations, demographic (body size, age, race, 
gender) data, laboratory data (hepatic and renal function), med ical history (colonic resection), 
and clinical trial ide ntifier.  These data will be analyzed usi ng methods appropriate for sparse 
data (mixed-effects mo deling using NONMEM). 
 Polyamine Sample Collection (Normal Mucosa Biopsy, Random Urine  Sample) 
Subject tissue samples will undergo a baseline polyamine assay (examination of grossly normal 
rectal mucosal cup forcep biopsy and random urine sample - minimum 15 mL) pre-treatment, as a component of the screening pr ocess, and at eac h endoscopy/pro ctoscopy evaluation.  Collected 
tissue and urine samples will be processed, stored, and shipped to a central laboratory according to procedures provided in the study manual. 
For subjects who have signed the Optional Research Use of Biosp ecimens portion of the 
informed consent, left over urine  or tissue samples may be used  for exploratory assessment of 
levels of expression of RNA, proteins, or other molecules, such as polyamines, in the polyamine 
synthesis pathway, the APC signaling pathway, and other related  pathways.  Analysis may 
include mutation status for genes  involved in the polyamine synthesis pathway, APC pathway, or 
other FAP related pathways. 
 Pharmacogenomic and Genetic Testing Sample Collection 
Subjects will have 10 mL of peripheral blood collected in an ED TA vacutainer tube during their 
baseline/screening visit for subsequent correlative science res earch.  Collected blood samples 
will be processed and shipped to a central laboratory according  to procedures provided in the 
study manual. 
For subjects who have signed the Optional Research Use of Biosp ecimens portion of the 
informed consent, left over blood samples may be used for explo ratory assessment of levels of 
expression of RNA, proteins, or other molecules, such as polyam ines, in the polyamine synthesis 
pathway, the APC signaling pathway, and other related pathways.   Analysis may include 
mutation status for genes involve d in the polyamine synthesis pathway, APC pathway, or other 
FAP related pathways.   
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102659] Preferences 
For this study, we plan to use four (4) instruments to measure HRQoL and subject preferences or 
utilities.  These instruments include the EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and a 
modified Cancer Worry Scale. 
• The EORTC QLQ-C30 is a self-administered quality of life questi onnaire70 with multi-
dimensional scales.  It consists o f both multi-item scales and single item measures, 
including five functioning domains, a global quality of life domain, three symptom domains and six single items.  
• The EORTC QLQ-CR29 gastrointestinal / colorectal sub-module
71 is composed of 4 
functional and 18 symptom relate d sub-scales.  The 4 functional scales include body 
image, weight, anxiety and sexual function.  The symptom relate d scales include single 
item and multi-item questions c oncerning stool frequency, bleed ing and mucous 
discharge, stool leakage, abdomin al bloating, flatulence, embar rassment and site-specific 
pain among others. 
• The EuroQol EQ-5D is a standardized instrument for use as a mea sure of health outcome 
and is applicable to a wide range of health conditions and trea tments.72,73  It provides a 
simple descriptive profile and a single index value for health status. 
• The Cancer Worry Scale74 is a brief psychometric instrume nt that was designed to assess 
both the frequency of worrying about “getting cancer some day” and measuring the 
impact of worry on mood and performing daily activities.  This scale was originally 
developed by [CONTACT_799391].  
The validity and reliability of both the QLQ-C30 and the QLQ-CR29 questionnaires have been studied by [CONTACT_799392].  
HRQoL measures will be obtained at baseline, month 3, at every interim endoscopy visit, and at 
end of treatment.  For each single item or multi-item sub-scale, a linear transformation will be applied to standardize raw scores to range between 0 and 100.  HRQoL secondary endpoints will 
include all single item or multi- item sub-scales from both the EORTC QLQ-C30 and QLQ-CR29 
and subjects will be considered as deteriorated (or improved) f or a given singl e item or multi-
item sub-scale if their change score from baseline was [ADDRESS_1102660] preferences (or ut ilities) will also be assessed.  
Data will be collected at baseline, month 3, at every interim e ndoscopy visit, and at end of 
treatment and preference weight s among the treatment arms will be determined using the 
EuroQol EQ-5D assessment o f individual health states.
72,73  Quality-adjusted survival among the 
three treatment arms will be gen erated by [CONTACT_799393] a specified health state.  The modified version of the Cancer Worry Scale will also be adm inistered at baseline, month 3, 
at every interim endoscopy visit,  and at end of treatment and i t will be scored according to the 
guidance provided by [CONTACT_799394].
74 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  51 
 Dietary Assessment 
The Food Frequency Questionnaire  (FFQ) is the most common dieta ry assessment tool used in 
large epi[INVESTIGATOR_667433].  The self-admin istered FFQ booklet asks 
participants to report the freque ncy of consumption and portion size of approximately 125 line 
items over a defined period of t ime (e.g. the last month; the l ast three months).  Each line item is 
defined by a series of foods or beverages.  Additional questions on food purchasing and 
preparation methods enable the analysis software to further ref ine nutrient calculations.  The 
FFQ was developed by [CONTACT_667461] ( NASR) of the Fred 
Hutchinson Cancer Research Center.  NASR periodically updates i ts standard FFQ to reflect 
U.S. food consumption patterns and major changes in the market place.82,83  Data from the FFQ 
will be analyzed using a polyamine database69 and will calculate the average daily levels of 
putrescine, spermidine, and sper mine in the diet.  Dietary asse ssments via the FFQ will be 
obtained at baseline, months 12, 24, 36 and 48/end of treatment for subjects at North American 
(U.S. and Canada) sites only.  The results of the FFQ will be u sed to corroborate results from 
another recent trial84 that indicate consumption of a  diet high in polyamines is asso ciated with 
reduced treatment efficacy.  The results of this trial along wi th the earlier findings of Zell et al40 
could lead to dietary restrictio ns in combination with the combined eflornithine-sulindac therapy. 
11. ASSESSMENT OF SAFETY 
 Cardiac Risk 
All subjects will undergo a baseline medical history evaluation  and EKG for cardiovascular 
disease risk assessment.  Subjects with cardiovascular risk fac tors as defined in Section 6.[ADDRESS_1102661] throughout the study via ongoing adverse event assessment s and periodic EKG evaluations 
at baseline, and months 3, 6, 12, 18, 24, 30, 36, 42 and 48/end  of treatment.  
 Ototoxicity Risk 
All subjects will undergo air conduction audiometry for hearing  impairment as part of the 
screening process and at months 12, 24, 36 and 48/end of treatm ent.  Subject diaries will indicate 
the presence of symptoms and will instruct the subject to conta ct the treating doctor for 
assessment. These data will not be used to exclude subjects from this study.  
At months 3, 6, 12, 18, 24, 30, 36, 42 and 48/end of treatment,  the subject will undergo a clinical 
assessment for ototoxicity adverse events symptoms by [CONTACT_799395]. 
 Gastrointestinal Risk 
Subject’s diaries will indicate presence of symptoms and will i nstruct the subject to contact [CONTACT_799396] .  Stool will be self-assessed by [CONTACT_799397].  If so, treating doctor will be contact[CONTACT_799398].  Subject 
will perform stool assessments, which will be recorded in their  diary. 
At months 3, 6, 12, 18, 24, 30, 36, 42 and 48/end of treatment,  the subject will undergo a clinical 
assessment for gastrointestinal adverse events symptoms by [CONTACT_799399]. 
  
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102662]’s off study treatm ent or off study date.   
Adverse events and serious adverse events must be recorded care fully and completely on the 
case report forms and SAE report forms.  Adverse event reportin g and grading will be done 
using the NCI Common Terminology Criteria for Adverse Events (C TCAE), Version 4.03, 
(http://evs.nci.nih. gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf).   
Serious adverse events must be reported to the Institutional Re view Board (IRB)/Independent 
Ethics Review Committee (IEC)/Research Ethics Board (REB) by [CONTACT_3433] e Investigator and to 
regulatory authorities (FDA, National Health Authorities) by [CONTACT_3433] e Sponsor, according to 
established policy and regulatory requirements.  Adverse events  will also be coded to an organ 
system class.  Summaries of safety  data will be completed for the study population. 
 Adverse Events 
Adverse event means any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related (FDA definition)  and is defined by [CONTACT_799400] a su bject or clinical trial subject 
administered a medicinal product and which does not necessarily  have a causal relationship with 
this treatment. 
An adverse event (also referred to as an adverse experience) ca n be any unfavorable and 
unintended sign (e.g., an abnorma l laboratory finding), symptom, or disease temporally 
associated with the use of a drug, without any judgment about c ausality.  An adverse event can 
arise from any use of the drug a nd from any route of administra tion, formulation, or dose, 
including overdose. An adverse reaction means any adverse event caused by [CONTACT_33641].  Adverse reactions are a subset 
of all suspected adverse reactions for which there is reason to conclude that the drug caused the 
event. 
An adverse event does not include: pre-existing disease, condit ions, or laboratory abnormalities 
present at the start of the study that do not worsen in frequen cy or intensity; situations where an 
untoward medical occurrence has not occurred (e.g., hospi[INVESTIGATOR_799318]/convenience admissions); the disease being studied or signs or symptoms 
associated with the disease unless more severe than expected for the subject’s condition. 
For the FDA, an unexpected adverse event is an event that is no t listed in the Investigator’s 
Brochure (IB) at the specificity o r severity observed or is men tioned in the IB as occurring with a 
class of drugs or as anticipated  from the pharmacological properties of the drug, but not 
mentioned as occurring with the  drug(s) under in vestigation. 
The Reference Safety Information (RSI) is located in the IB Ver . CPP-201-IB08 and subsequent 
versions, which is to be used for the purposes of determining e xpectedness and SAE/S[LOCATION_003]R 
reporting.   
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  53 
 Serious Adverse Events 
A serious adverse event determi ned by [CONTACT_46248][INVESTIGATOR_799319] 
1. Death; 
2. A life-threatening event (pl aces the subject at immediate ri sk of death); 
3. Requires in subject hospi[INVESTIGATOR_799320]; 
4. Persistent or significant incapacity or substantial disrupti on of the ability to conduct 
normal life functions; 
5. Congenital anomaly/birth defect; 6. Important medical events (IME s) may be considered serious wh en, based on medical 
judgment, they may jeopardize the subject and require intervention to prevent one of the 
above serious outcomes. 
An adverse event or suspected adverse reaction is considered “life-threatening” if, in the view of either the Investigator or Sponsor, its occurrence places the subject at immediate risk of death.  It does not include an adverse even t or suspected adverse reaction  that, had it occurred in a more 
serious form, might have caused death. 
 Reporting of AEs, SAEs, Serious and Unexpected Adverse Experien ces 
Subject Reporting of an Adverse Event 
Subjects will be instructed to contact [CONTACT_799401].  
The Investigator will question each subject regarding symptoms at the time of each physical 
examination/review of body systems.  All adverse experiences, i ncluding duration and severity 
will be captured in the Case Report Forms provided by [CONTACT_1034]. All adverse events are to be doc umented from the day the subjec t receives his/her first study 
treatment through [ADDRESS_1102663]’s off study treatme nt date (date of last dose). 
Reporting Serious Adverse Events (SAEs) to Sponsor Serious Adverse Events are to be documented and reported to the  Sponsor from the day the 
subject receives his/her first  treatment through [ADDRESS_1102664]’s off study treatment 
date.  SAE follow-up needs to con tinue until the event is resolved or returned to baseline. Serious 
Adverse Events occurring to a s ubject after the 30-day off study treatment date should be 
reported to the Sponsor only if the SAE could be attributed to study treatment. 
An Investigator shall report to the Sponsor via telephone, fax or e-mail, any Serious Adverse 
Event regardless of causality, within [ADDRESS_1102665] (IRB)/Independent E thics Committee 
(IEC)/Research Ethics Board (REB) 
SAE’s must be reported to the IRB/IEC/REB by [CONTACT_737] a ccording to each institution’s 
policy and procedures. Reporting to Regulatory Authorities and Participating Investiga tors 
The Sponsor will notify appropriate regulatory authorities by f ax, telephone or in writing of any 
unexpected fatal or life-threatening suspected adverse reaction  associated with the use of the 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  54 study drug as soon as possible, but in no event later than 7 ca lendar days after initial receipt of 
the information. 
The Sponsor shall notify appropria te regulatory authorities and  all participating Investigators in 
writing via IND safety reports/CIO MS reports of any serious and unexpected adverse experience 
associated with the use of the drug; and such reports shall be made as soon as possible but in no 
event later than 7 or 15 calendar days after the Sponsor’s init ial receipt of the information, 
depending on the reporting requirements. 
The Sponsor will submit IND safety reports/CIOMS reports to FDA , Heath Canada, EMA, and 
National Competent Authorities as required, and all participati ng Investigators no later than [ADDRESS_1102666]. 
The Sponsor will report all adverse experiences to the U.S. FDA  in Annual Reports to the IND, 
and to all applicable regulatory authorities annually as required, in addition to the final report of the clinical trial. 
 Reporting of Pregnancy 
If following initiation of study treatment, it is discovered th at: 
• A female subject is pregnant or may have become pregnant at the  time of investigational 
drug exposure, the investigational drug will be immediately discontinued until further assessment. If it is determined that study drug should be perma nently discontinued, all study 
required procedures for study di scontinuation and follow-up mus t be completed unless 
contraindicated by [CONTACT_634650].   
• For male subjects, if their partner is pregnant or may have become pregnant, the male subject must agree to the use of a barrier birth control method as stat ed in section 6.1 #11 [Male 
subjects (including men who have had vasectomies) whose partners are pregnant should use condoms while the partner is pre gnant. If the partner is still pregnant when the subject goes 
off study, the subject should continue condom  uses for at least 2 weeks afterwards] .  If he 
does not agree to the above, he will be terminated from the stu dy and all study required 
procedures for study discontinua tion and follow-up must be comp leted. 
The Investigator must notify th e Medical Monitor within [ADDRESS_1102667]’ s off study treatment date, and concomitant medications for AEs 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102668]-EOT, will be coded to therapeu tic drug classe s and generic 
names using, for example, the WHO Drug classification dictionar y. 
Subjects are to be ins tructed to not take the following medicat ions or supplements while on study 
treatment: oral corticosteroids ( such as prednisone), NSAIDS (such as ibuprofen, celecoxib, 
aspi[INVESTIGATOR_799306] 700 mg weekly ), diflunisal, supplements co ntaining omega-3-fatty acids 
(such as fish oil), an ticoagulants (such as warfarin, Pradaxa®, Eliquis®, Plavix®, and other direct 
thrombin inhibitors), fluconazole, lithium, furosemide and thia zides, DMSO, methotrexate, 
probenecid, propoxyphene hydrochloride, Tylenol® (acetaminophen) preparations containing 
aspi[INVESTIGATOR_799321]. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  56 12. STATISTICAL CONSIDERATIONS 
The Statistical Analysis Plan (SAP) will focus on analysis of the primary and secondary 
endpoints, in order to assess the extent to which the combination of CPP-1X 750 mg daily + [ADDRESS_1102669] occurrence of any FAP-related event in Familial Adenomatous Polyposis (FAP) patients.  Eligible patients who have given informed consent will enter the study with the intent to participate for the full tre atment period.  Accrual is expected to 
take 12-[ADDRESS_1102670] 50 per  treatment group.  
Patients will be randomized to one of three treat ment groups wi thin the prognostic strata defined 
in Section 4.3 in equal proportions (i.e., 1:1:1 randomization) : 1) CPP-1X plus sulindac, 2) CPP-
1X placebo plus sulindac, 3) CPP-1X plus sulindac placebo.   The study is double blinded, so neither subjects nor Investigat or nor Sponsor will be aware of 
treatment assignment. For the primary efficacy analyses, we will use the intent-to-treat (ITT) population defined as all 
subjects that have been randomized to one of the three study ar ms.  Subjects will be analyzed in 
the group to which they were randomized, whether or not they re ceived their assigned treatment, 
any treatment whatsoever, or completed their treatment course a nd follow-up.  The safety 
outcome will be analyzed using all subjects in the ITT population who received at least one dose of study drug (safety population).  
 Primary Efficacy Objective and Analysis 
The primary objective of this tria l is to determine whether the  combination of CPP-1X + sulindac 
is superior to either single-agent treatment individually in de laying the time from the date of 
randomization to the date of the first occurrence of any FAP-re lated event.  Section 8.2.14 
provides complete detail on FAP-related events. 
Thus the primary objective contai ns two treatment comparisons:  
1. CPP-1X placebo + sulindac active vs. CPP-1X active + sulindac active,  
and 
2. CPP-1X active + sulindac placebo vs. CPP-1X active + sulindac active 
These two treatment comparisons will be performed sequentially as described below. 
The combination of CPP-1X activ e + sulindac active is specified  as the reference treatment 
group because it is common to both comparisons.  In addition, because the purpose of the combination treatment is to delay the time from randomization to FAP-related disease progression compared to single-ag ent treatments, formulating th e hypothesis tests in this manner 
will allow a positive rather than a negative Z-score for the test statistic to be interpreted as 
supportive of this purpose. 
Each comparison will be performed  at the 2-sided 0.05 level of statistical significance. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  57 As explained in the Statistical A nalysis Plan, the decision to seek regulatory approval based upon 
the results of the primary objective will be taken sequentially . 
CPP will sequentially perform the two primary comparisons as pa rt of the primary analysis, each 
at the 2-sided p = 0.[ADDRESS_1102671] serves as a gatekeeper 
for the second (i.e., no declaration of significance in the sec ond comparison will be made if the 
first comparison is not signifi cant at the 0.05 level).  Therefore, the type I erro r in the sequential 
testing is well controlled.  In addition, because both tests mu st be significant for EMA approval, 
the type I error of the second test in the sequence is less tha n 0.05.  
The analytic method for the primary analysis will be a time-to- event analysis using the stratified 
log-rank test.  The stratified Cox proportional hazards regress ion models will be used for 
secondary assessments.85  Graphical analyses (log-minus-log plots) will be used to chec k the 
assumption of constant hazard ratios.  For the primary analysis, two stratified log-rank tests will 
be performed with treatment coded  as a binary value (i.e., 0 or 1). Time to event curves will be 
displayed using the meth od of Kaplan and Meier86.  Additional analyses involving the overall 3-
treatment group comparison and use of additional study populati ons or the two pairwise 
treatment comparisons, will be performed as supplemental analys es. 
If an FAP-related event occurs, that patient will be said to ha ve an observed or uncensored event 
and will be considered a treatment failure.  If a subject withd raws, that subject will be treated as 
a censored observation as of the last recorded clinic visit (en doscopic disease assessment). 
If a subject has not progressed or is not known to have died at  the date of analysi s cut-off, time to 
first FAP-related event will be censored at the date of the las t adequate endoscopy procedures 
before the cut-off date.  Simila rly, if a subject discontinues study participation due to toxicity and 
begins receiving other therapy, t he time to FAP event will be c ensored at the date of the last 
adequate endoscopy procedure.   
Prior to the primary analysis, balance will be assessed between  the three arms in terms of key 
potential confounders measured at the baseline visit.  If any o f these variables is found 
significantly out of balance acro ss the three groups using a [ADDRESS_1102672] 
(adjusted stratified log-rank te st) will serve only as a secondary analysis to aide in the 
interpretation of the primary result. 
 Secondary Efficacy Outcome and Analysis 
Any improvement observed by [CONTACT_799369] (UGI) and lower 
gastrointestinal (LGI) visuali zation (i.e. endoscopy and colonoscopy) at the 6 and 12-month 
study visits will be described using the variables UGI Observed Improvement (UGIOI), and LGI 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  58 Observed Improvement (LGIOI).  E ach patient will have one pair of UGIOI and LGIOI 
outcomes (refer to the Statistical Analysis Plan for more detail). 
UGIOI and LGIOI are binary outcomes derived from numerical determinations (henceforth, 
“investigator change scores” or more briefly, “scores”) assigned by [CONTACT_799402], using a scale (–2, –1, 0, +1, +2) which corresponds,  respectively, to the investigator’s 
overall qualitative assessment of: much worse, worse, no change , improved, much improved.  At 
the month 6 procedures the investigator scores UGI and LGI findings as changes from baseline.  
At the month 12 procedures, the UGI and LGI findings are scored  relative to the month 6 
procedures. 
The UGIOI (and respectively, the LGIOI) secondary endpoint inde pendently summarizes the 
corresponding 6- and 12-month investigator change scores accord ing to whether or not there was 
any positive improvement  at either month 6 (compared to  baseline) or at month 12 (compa red to 
baseline or month 6), under the condition that there be no worsening at either timepoint 
(compared to the preceding time point).  Refer to the Statistica l Analysis Plan for further details 
on the planned analysis.  
 Other Secondary Outcomes 
Other secondary outcomes will include the following: To explore how study treatment group relates to o ther efficacy outcomes, genotype, phenotype, 
disease locations and endoscopic findings, additional analyses are planned.  These analyses will 
be performed in the ITT group, the Per Protocol Group, and other defined subgroups (see 
protocol Section 12.5, Populations  for Analysis and the Statist ical Analysis Plan) wherever 
possible and will all be clearly noted as such. 
The UGIOI and LGIOI outcomes will be tabulated and summarized u sing the month 6 visit 
scores, alone.  Similarly, the UGIOI and LGIOI outcomes will ta bulated and summarized across 
all study visits. 
As both part of the primary analysis, and further explored in these additional analyses, median 
time to event for each treatment group will be determined. This  will be explored for each of the 
study populations (i.e. ITT, per protocol, and others), study d isease stratum groups, and in the 
Disease Site subgroups (refer to t he Statistical Analysis Plan for more details). 
Pharmacokinetic data (plasma concentrations measured at patient visits) will be used to estimate population pharmacokinetic paramet ers for the CPP-1X (eflornith ine), sulindac, and CPP-1X 
(eflornithine) + sulindac treatment groups (i.e., for each anal yte for those patients on 
combination treatment). 
The subcategories of FAP events will be explored  by [CONTACT_799370], and by [CONTACT_799403] (refer to the Statistical Analysis Plan). The presence or absence of ODC polymorphisms, including the sin gle nucleotide polymorphisms 
(SNPS) rs2302615 and rs2302616 and th eir relation to treatment group and outcome will be 
tested with the likelihood ratio test. The excretion of 5 urinary polyamines (diacetylspermine, n1-ace tylspermidine, n8-
acetylspermidine, decarboxylated SAM, and putrescine) will be a ssessed in relation to treatment 
group and outcome, using the sin gle point concentration data ga thered from the urine samples 
harvested at each study visit. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  59 Patient reported health related quality of life measures will b e evaluated using HRQoL (refer to 
Statistical Analysis Plan for more details). 
Tissue and dietary polyamine levels, as collected at patient st udy visits will be analyzed together 
with the results of the dietary questionnaires and related to treatment group and study outcomes. 
Safety outcome data and analyses are described in detail in the Statistical Analysis Plan. 
 Sample Size Determination 
The primary endpoint of this tri al, time to meaningful clinical  events in an orphan disease 
population, is novel and to date there are no published trials to draw upon that have incorporated 
the exact FAP-related endpoint of this trial.  Available data from primary literature sources include clinical studies where polyps were counted over a fixed  time period, in different FAP 
populations (see Appendix E for tabulated listing).   
From these data a reasonable range of event frequencies was estimated to produce the sample 
size and power calculations incor porated into this trial.  Thes e time-to-event estimates were 
reviewed by [CONTACT_799404][INVESTIGATOR_799322] e study design.  The following 
reflects the possible range of FAP events it was thought plausi ble to observe. 
 Power Calculation Assumptions 
1) The level of statistical si gnificance is set at 0.05, using a 2-sided stratified log-rank test for 
time-to-first FAP-related event in continuous time, for each of  the two between-group 
comparisons (i.e. single agent sulindac vs. CPP-1X plus sulinda c and single agent CPP-1X vs. 
CPP-1X plus sulindac).  The only covariates in the log-rank tes t will be the treatment groups; 
2) A doubling of the two-year event-free propor tion from either  of the single agent treatment 
arms to the combina tion treatment group;  
3) Power of at least 85% to detect the above-mentioned treatmen t effect comparing either of the 
two single treatment arms to the combination arm; 
4) The two single-agent treatme nt groups have approximately the  same event rate. 
The following calculations are bas ed on our review of limited s ingle-agent data for eflornithine 
and sulindac, where FAP clinical  trial primary endpoints involved polyp counting.  Extrapolating 
these data to two-year event-fr ee proportions implies a single overall two-year event-free 
proportion of at least 60% to 70%  for the combination treatment group and 30% in each single 
agent treatment group.   
 Hazard Rates 
Because the power of time-to-event analyses depends on the total number of observed primary endpoints (“events”) and the haza rd ratio in a given two-arm co mparison of a single-agent versus 
combination therapy, we translate the above doubling of two-yea r event-free proportions into 
hazard ratios under a simplifying assumption of exponentially distributed tim e-to-event.   
Furthermore, the stratified log -rank test is an optimal test (l ocally most powerful) under the 
assumption that the ratio  of the two groups’ hazard functi ons remains constant over time  (the 
proportional hazards assumption).  Note that the much stronger assumption, that the individual 
hazard functions themselves remain constant over time, would be  dubious in this trial.  
Therefore, irrespective of how  the two-year event-free proporti ons are translated into hazard 
ratios, it is the latter which forms the design alternative parameter  for the trial. 
Under the exponential assumption , the hazard ratio (HR) compari ng one treatment arm to 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102673] a two-year event-free pr oportion of 60%, which is 
double that of the 30% two-year event-free proportions assumed for the single-agent arms, the 
HR is {log(0.60) / log(0.30)} = 0.4243.  This is the design alternative hazard ratio for this trial  
as it represents the minimum clinically meaningful treatment ef fect desired for the combination 
therapy compared to either single-agent therapy.  Insofar as th e combination therapy may have a 
two-year event-free proportion of at least  60%, and may prove to be perhaps 70% or greater, the 
design alternative HR of 0.4243 is  conservative; the true (albe it unknown) HR is thought 
possibly to range from 0.4243 down to 0.30 = {log(0.70) / log(0.30)}. 
Given that the primary hypotheses are stated in terms of comparing either single-agent arm to the 
combination arm, we note that the  equivalent design alternative  hazard ratio becomes  
{log(0.30) / log(0.60)} = 1/0.4243 = 2.357. For the anticipated range of haza rd ratios, 25 to 49 events wou ld be needed for each two-group 
comparison at the 2-sided 0. 05 level to achieve 85% power
87,88   Assuming two-year event 
proportions of 70% in either of the two single-agent groups and  30% to 40% in the combination 
arm with [ADDRESS_1102674] 85% power under the design alternative.  The standard deviation around the expectation of 55 events is 4.74, so observing the required number of 49 events or more would be highly likely (the probability is about 91%).  If  the total number of events in 
either comparison were only 43, there will still be 80% power t o declare a significant treatment 
difference under the design alternative of 0.4243. 
As the two-year event proportion in the combination arm decreas es from 40% with a 
corresponding decrease in the ha zard ratio, the likelihood of o bserving the required number of 
events to maintain 85% power act ually increases.  For example, at the lower expectation of 50 
events arising from an assumed  two-year event proportion of 30%  in the combination arm, the 
standard deviation of the total number of events in a two-arm c omparison decreases to 4.58 and 
the probability that the observed number of events will exceed the 25 required to achieve 85% at 
a HR of 0.30 is virtually certain. 
 Populations for Analysis 
 Intent-to-Treat (ITT) Population  
The intent-to-treat population in cludes all patients that have been randomized to one of the three 
study arms (CPP-1X plus sulindac, CPP-1X placebo plus sulindac,  CPP-1X plus sulindac 
placebo).  Patients will be analyzed in the group to which they  were randomized, whether or not 
they received any treatment or completed their treatment and fo llow-up. 
 Safety Population 
The safety population is defined as all ITT patients who receiv ed at least one dose of study 
medication.  Patients who do not r eceive any study treatment (C PP-1X or sulindac or their 
combination) are excluded from this population.  Patients will be analyzed in the treatment group 
for which actual treatment was initially received.   
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  61 
 Per Protocol Population 
The per-protocol population is defined as the subset of the ITT  population that fulfill all protocol 
eligibility, intervention, and outcome assessments. 
 Other Populations 
Within the entire study patient population there will be subset s who did not receive the full 
course of per protocol treatment .  The major indicators for premature withdrawal are delineated 
below.  The patient diary and pi[INVESTIGATOR_799323]. 
For exploratory and sensitivity analyses the following subsets will be included in secondary 
analyses: 
• Subject withdrawn for personal reasons 
• Treatment discontinued because of disease symptoms 
• Treatment discontinued because of patient symptoms 
• Compliance <80% treatments taken 
• Treatment discontinued because of intercurrent medical or surgical illness. 
 Other Statistical Methods  
 Demographic and Baseline Characteristics 
Patients in the three populations (ITT, Safety, Per Protocol) w ill be summarized for demographic 
and baseline characteristics in a descriptive fashion.  Namely,  categorical and continuous-valued 
data will be displayed using standard summary statistics (e.g.,  frequency tables, n, means, 
medians, standard deviations, and ranges).  Data will be presen ted per group and overall.   
Demographic features summarized will include age, gender, race,  institution at which each 
patient registered, and country a mong other features.  Baseline characteristics will include 
laboratory values and disease-related characteristics, as well as any other relevant values.  
Categorical data will be compared among groups using chi-square d methods, while continuous-
valued data will be compared using standard nonparametric metho ds (e.g., the Kruskal-Wallis 
test).[ADDRESS_1102675] to follow-up.  Additional summaries will 
include reasons for patients discontinuing treatment and/or mod ifying treatment dosages.  A 
listing of screened and ineligible  patients along with the reas on for each also will be summarized. 
 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102676] p-values and 95% 
confidence intervals by [CONTACT_799405]91. 
For continuous endpoints, standar d analysis of covariance (ANCO VA) methods will be used as 
the primary approach to compare treatment groups at end of trea tment with the following 
covariates: baseline value, binary indicator variables for the two highest-risk stratification levels 
used in the randomization (using the lowest-risk, i.e., rectum/pouch polyposis, group as the 
reference stratum), and a binary treatment indicator (1=combina tion treatment, 0=single 
treatment). 
For ordered categorical data, a K ruskal-Wallis nonparametric te st for ordered categorical 
response will be used to compare treatment groups.89 
Treatment-emergent adverse events will be enumerated and analyz ed according to the incidence, 
intensity, type of adverse events, and clinically significant c hanges in the patient’s physical 
examination findings, vital signs and clinical laboratory resul ts.  Safety variables will be 
tabulated and presented for all patients in the safety and per- protocol populations as defined 
previously.  Adverse events will be graded and coded using the NCI Common Te rminology Criteria for 
Adverse Events (CTCAE, Version 4.03).  Treatment-emergent event s will be tabulated, where 
treatment-emergent is defined as any adverse event that occurs after administration of the first 
dose of study drug and through [ADDRESS_1102677] dose of study  treatment but worsens in intensity.  
Events that are considered relat ed to treatment (possibly, prob ably or definitely drug-related) 
also will be tabulated separatel y.  Tables that enumerate adverse events by [CONTACT_799406].  Deaths, serious adverse events and events resulting in study discontinuation will be 
tabulated in data listings including additional relevant inform ation on each patient.  Tables will 
be presented both overall (all arms combined), by [CONTACT_799407] t group separately, and by [CONTACT_79371]. 
Where appropriate, statistical com parisons between treatment ar ms will be provided using the 
above-mentioned methods for an alysis of categorical data. 
 Subgroup Analyses 
Subgroups will be analyzed in the spi[INVESTIGATOR_799324] s including but not limited to the 
various study populations and sepa rately within each disease-prognosis stratum. 
 Health Related Quality of Life (HRQoL) 
For this study four (4) instruments to measure HRQoL and patien t preferences or utilities will be 
administered to subjects at baseline and months 3, 6, 12, 18, 2 4, 30 36, 42 and 48/end of 
treatment.  These instruments include the EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and 
a modified Cancer Worry Scale. The validity and reliability of both the QLQ-C30 and the QLQ-CR29 questionnaires have been 
studied by [CONTACT_799392].   For each single item or 
multi-item sub-scale, a linear transformation will be applied t o standardize raw scores to range 
between 0 and 100.  HRQoL secondary endpoints will include all single item or multi-item sub-
scales from both the EORTC QLQ-C30 and QLQ-CR29 and patients will be considered as 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  63 deteriorated (or improved) for a given single item or multi-item sub-scale if their change score 
from baseline was 10 points or more on the standardized scale.   
Patient preferences (or utilities) will also be assessed using the EuroQoL EQ-5D.  Preference 
weights among the treatment arms will be determined using the E uroQol EQ-5D assessment of 
individual health states.72,73  Quality-adjusted survival am ong the three treatment arms will be 
generated by [CONTACT_799408] e spent in a specified health state.  
The modified version of the Cancer Worry Scale will also be administered and it will be scored 
according to the guidance provided by [CONTACT_799394]74. 
HRQoL data will be obtained while patients are receiving treatm ent.  At the time of an FAP-
related event (primary outcome), additional long-term clinical follow-up and QoL data will not 
be obtained as part of this tr ial.  Hence, HRQoL trends compari ng the nine subsets will be 
obtained, but comparative longit udinal analyses defining the im pact of an FAP-related event on 
QoL will not be feasible until subsequent long-term studies are  performed. 
 Dietary Assessment 
The FFQ was developed by [CONTACT_799409] (NASR) of the Fred 
Hutchinson Cancer Research Center. NASR periodically updates it s standard FFQ to reflect U.S. 
food consumption patterns and major changes in the market place .82,83  Data from the FFQ will 
be analyzed using a polyamine database69 and will calculate the average daily levels of 
putrescine, spermidine, and sper mine in the diet.  Dietary asse ssments via the FFQ will be 
obtained at baseline, months 12, 24, 36, 42 (only if end of tre atment) and 48/end of treatment for 
subjects at North American ( U.S. and Canada) sites only. 
 General Procedures for Handling of Missing Data 
Every reasonable effort will be made to continue follow-up of all study participants, including those who discontinue randomized  therapy, to prevent data loss.   It is recognized that missing 
values represent a potential source of bias in a clinical trial  and so every effort will be undertaken 
to fulfill all the requirements of the protocol concerning the collection and mana gement of data. 
For the primary time to event analysis, the only possible patie nt outcome is an observed FAP-
related event, or a censored obs ervation.  Participants who are  lost to follow-up for reasons 
deemed unrelated to their health status will be censored at the time their status is last known, based upon data collected at the last recorded clinic visit.  F or patients who may have missed a 
study visit, every effort will be  made to obtain endoscopic res ults at their close-out visit and 
those endoscopy results will be used for the primary analysis.   
Secondary analysis data include the presence of a specific genetic mutation, and urinary metabolite concentrations (See Section 12.2). The main analysis of the secondary objectives will 
include collected data only, without imputing or weighting data  to compensate for missing data.  
For sensitivity analyses involving secondary endpoints with mis sing data, we will use the last 
observation carried forward (LOCF ) method to complete the missing data.  Any sensitivity 
analysis that incorporates LOCF will be clearly noted.  Sensitivity analyses of these data will be performed to explore study results more fully, in a manner consistent with ICH Guidance “ E9 
Statistical Principles for Clinical Trials (February, 1998) ”. 
All available efficacy and safet y data will be included in data  listings and tabulations.  Data that 
are potentially spurious or erroneous or appear as outliers will be examined using standard data management operating procedures, prior to database lock and statistical analysis. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  64 
 Interim Monitoring and the Data Monitoring Committee 
A Data Monitoring Committee (DMC) will oversee the performance and safety conduct of this 
study.  The DMC will consist of at least three members (two MDs  and one statistician as voting 
members) who will receive confidential reports on a periodic basis.  The DMC will be responsible for decisions regarding possible termination of the  study for either futility or safety 
reasons. 
A detailed DMC Charter will be produced separately by [CONTACT_799410].  It is anticipated 
that any reviews of study data will be performed in a blinded m anner, looking at pooled data (all 
treatment groups combined into one group) to assess mission-cri tical parameters such as overall 
recruitment and event rates.  A ny pre-specified interim analyse s will be conducted in a blinded 
manner.  Of course, patient safet y issues take precedence over bias-protection and control of type 
I error, and so the DMC will have the privilege of breaking the  blind on a need-to-know basis if 
safety issues of concern arise in order to consider risk-benefit issues.  Details concerning DMC responsibilities and duties may be submitted as a stand-alone document to the FDA and EMA, including items such as specifi cation of early termination rule s and other matters as the DMC 
deems to be important and relev ant to the ethical conduct of th is study.  
CPP will inform the DMC that there will be two study evaluation s for the DMC to consider 
during the trial, one interim look for sample size reassessment  and one look for futility. 
The method for reassessment of sample size is based upon the FDA Guidance, “Adaptive Design 
Clinical Trials for Drugs and Biologics (February 2010) ”.  There will be no hypothesis testing.  
The DMC will assess the observed trial event rate based on pool ed data only.  They will make a 
recommendation to the Sponsor on whether the pooled event rate is sufficient to preserve the 
integrity of the trial, and if not, to recommend a revised samp le size.  For this assessment the 
study statistician will, if possible, estimate the overall observed event rate and 90% confidence interval.  This assessment will be performed using data from a single time point, when 
enrollment is approximately 95% complete.  If this type of assessment is not possible, then as 
assessment will be performed taking into consideration the tota l number of subjects randomized, 
total number of events, total n umber of dropouts, and cumulativ e study safety data. 
Prespecified Interim Efficacy and Futility Analysis 
A pre-specified interim efficacy and futility analysis will be conducted in a blinded manner.  The 
assessment will be performed after a total of [ADDRESS_1102678] occurred, which 
represents 50% of expected maxim um trial information, or as soo n thereafter as possible.  Refer 
to the Statistical Analysi s Plan for more details. 
The analysis will be performed for each of the two treatment co mparisons contained in the 
primary objective:  
1. CPP-1X placebo + sulindac active vs. CPP-1X active + sulindac active,  
and 
2. CPP-1X active + sulindac placebo vs. CPP-1X active + sulindac active  
The efficacy analysis will use a modified Haybittle-Peto stoppi [INVESTIGATOR_799325]-
rank Z-score.  If that Z-score equals or exceeds 3.[ADDRESS_1102679] oppi[INVESTIGATOR_799326].  Assuming this is not the case 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  65 and the trial continues to its planned end, the Z-score criterion for declaring significance at the 
5% level at the end of the trial will be increased in magnitude  to plus or minus 1.962 in order to 
preserve the overall type I erro r rate for the trial at 0.05. 
For the futility analysis, the D MC will be provided with the numerical value of the stratified log-
rank Z-score.  The futility analysis us es a one-sided futility stoppi[INVESTIGATOR_136045] Z = −0.50. That 
is, if the Z-score is less than or equal to −0.50, an investigation will be initiated to consider 
stoppi[INVESTIGATOR_799327]-agent treatment arms.  The futility 
stoppi[INVESTIGATOR_136045] Z = −0.50 is consistent with a conditional power of less than 20 %.  That is, 
assuming between [ADDRESS_1102680] occurred by [CONTACT_799411]-arm comparisons (where between 52 and 55 are expected), if the log-rank critical ratio Z-score 
were equal to −0.5 (or less) when one-half the expected total n umber of events had been 
observed (namely, 45 across all three arms), then under the des ign alternative hazard ratio of 
2.3569, there would be no more tha n a 20% chance of declaring a significant benefit of the 
combination therapy compared to the single agent therapy if the  trial were to continue to the 
planned end. In that case, it would be reasonable for the DMC to consider stoppi[INVESTIGATOR_799328].  The DMC will also be provided with the conditional power of the observed Z-score for each two-arm comparison. 
Any numerical values generated from the futility analysis (such  as Z-score, conditional power, 
etc.) must be treated as confid ential by [CONTACT_799412] t Statistician at the CRO.  If the 
DMC recommendation is to continue the study as planned, such numerical values will not be 
forwarded or conveyed in any manner to the Steering Committee, Sponsor, or any other parties. 
 Pharmacokinetic Analysis for Eflornithine and Sulindac 
The text that follows applies to each of the two compounds, eflornithine and sulindac.  Separate analyses will be performed for each drug. 
To perform the population pharmacokinetic analysis, a dataset w ill be constructed as follows: 
1. All subjects with at least one sample will be included in the a nalysis.  Actual sample time 
will be used in the analysis. 
2. Dosing history will be assembled based on CRF data.  Dosing rec ords will assume 100% 
compliance, except as documented in the CRF. 
3. The dataset will be constructed using a script in R (www.R-proj ect.org).  All steps will be 
documented.  All decisions regard ing handling of aberrant data will be documented. 
4. Covariate data (age, extent of  prior colectomy, body size, gend er, race, laboratory values, 
etc.) will be included in the dataset.  The dataset will be constructed using values 
obtained temporal to the time of sampling. 
The pharmacokinetic analysis wi ll be performed using NONMEM (ve rsion 7.1 or greater).  
Graphics will be created using PLT Tools (version 3.0 or greate r) using R (version 2.11 or 
greater).  Initially, linear comp artmental models will be appli ed to the data.  The choice between 
1-, 2-, and 3-compartment models will be based on the graphics and the minimum value of the 
objective function.  If graphics  suggest nonlinearity in pharmacokinetics with respect to dose 
and/or concentration, nonlinea r models will be evaluated. 
Once the optimal structural and e rror model has been determined , covariate effects will be 
assessed using a variety of tools including graphics of post ho c parameter estimates vs. 
covariates, a general linear m odel of parameters as a function of covariates, or an automated 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  66 covariate search (PLT Tools).  C ovariates will be incorporated into the model if they are 
physiologically appropriate, achieve statistical significance ( generally requiring a P value < 0.01 
in this exploratory environmen t), and improve the graphics. 
Once a final model is determine d, the model will undergo validation.  The strength of covariate 
effects will be determined us ing likelihood profiles.  Confiden ce intervals for parameter 
estimates will be determined us ing bootstrap techniques.  If ap propriate, a visual predictive 
check will be performed. 
All NONMEM outputs and graphics will be provided with the popul ation pharmacokinetic 
report.  Results will be summarized detailing the process of model building.  The report will 
include key graphics demonstrati ng the fit of the model to the data and covariate effects. 
 13. STUDY MANAGEMENT AND REPORTING PROCEDURES  
 Data Monitoring  
A Data Monitoring Committee (DMC) will oversee the performance and safety conduct.  The 
DMC will consist of at least three members (two MDs and one sta tistician as voting members) 
who will receive confidential reports on a periodic basis.  The DMC will be responsible for 
decisions regarding possible term ination of the study for eithe r futility or safety reasons, refer to 
Section 11, Assessment of Safety and Section 12.8, Interim Moni toring and the Data Monitoring 
Committee. 
 Patient Tablet Dispensing Record 
Three (3) month supplies of st udy drug(s) are issued in person or by [CONTACT_799413].  
Subjects will keep a written diary concerning their compliance in taking the four tablets daily. 
The drugs are to be taken at approximately the same time each d ay with food, preferably in the 
morning.  If the dose is missed, the tablets may be taken with mid-day or evening meals.  If an 
entire day is missed, this should be indicated in the weekly do se accountability in the medication 
diary, but double-dosing the fo llowing day is not allowed.  If the subject vomits within an hour 
after taking the tablets, the s ubject will record a missed dose in the diary. If the subject vomits 
more than [ADDRESS_1102681]’s next scheduled visit and an accounting of the medication will be performed and recorded by [CONTACT_799414]. 
 Investigator Documentation 
The Investigator will provide the Sponsor with a fully executed  FDA form 1572 including the 
Investigator’s dated curriculum vitae.  A current curriculum vi tae is also required for each sub-
Investigator listed on the FDA Form 1572.  A current dated curriculum vitae is defined as updated within [ADDRESS_1102682] evaluation.  The labo ratory’s certification, certification 
number and date of certification and the laboratory normal valu es will be provided.  Any changes 
in the clinical laboratory or la boratory values will be provide d promptly to the Sponsor who will 
report it to the FDA. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102683] be submitted to the I RB/IEC/REB for written 
approval.  The approval letter, signed by [CONTACT_1201]/IEC/REB Chair person, must refer specifically 
to the Investigator, the protoco l number and protocol title, th e protocol amendment number and 
the date of the protocol amendment.  A copy of the approval letter and revised informed consent 
document (if appropriate) must be sent to CPP.  A protocol amen dment may be implemented 
only after it has been approved by [CONTACT_1201]/IEC/REB and submitte d to the FDA and other 
regulatory agencies as appropriate.  In the case of a protocol change intended to eliminate an 
apparent immediate hazard to sub jects, the change may be implemented immediately, but the 
change must then be documented in  a protocol amendment and appr oved as described above. 
 Access to Source Data and Documents 
Monitors and/or auditors of CPP or representatives of the Sponsor must be allowed to visit and monitor all study site locations  periodically to assess the data, quality and study integrity.  The 
monitors and/or auditors will review study records (typi[INVESTIGATOR_897] C RFs) and directly compare them 
with the source documents and di scuss the conduct of the study with the Investigator and verify 
that the investigational site is compliant and continues to be acceptable.  In addition, the site may 
be audited by [CONTACT_799415], source documents 
and other study files.  The site must promptly notify CPP of an y inspections scheduled by 
[CONTACT_12721], and also  forward copi[INVESTIGATOR_799329]. 
 Investigational Agent Records and Accountability 
It is the Investigator’s responsibility to ensure that accounta bility records of drug use and 
disposition are maintained at th e study site and that the drug is maintained in a secure location 
under storage conditions prescri bed by [CONTACT_1034].  The site p harmacist or appointed 
investigational agent monitor wi ll be the individual completing  the records or logs for 
accountability and drug dispensing at each site.  The site phar macist must comply with all 
applicable regulations and guide lines.  The logs should include  the amount of drug received; 
amount currently on site, drug lo t or batch numbers; amount dispensed to each study subject with 
appropriate subject study identification numbers; non-study disposition (wastage, broken), amount returned to site and Sponsor, amount destroyed at study if requested.  CPP will provide forms to assist with drug inventory if the site does not have an established procedure that meets the requirements.  Drug inventory records will be inspected by [CONTACT_1034]’s study monitors during the period of study treatment.  Audits will be done to verify drug accountability.  If a site has been determined to be non-compliant with drug accountabilit y corrective action will be 
initiated. 
At the completion or termination of the study, all unused inves tigational agent will be returned to 
the repository unless authorized i n writing to be destroyed at the site.  If the drug is to be 
destroyed on site, appropriate policies and procedures at the s ite must be in place for proper 
disposal of chemotherapeutic agents.  These procedures will be reviewed by [CONTACT_2728]’s study 
monitors prior to providing wr itten authorization for on-site d rug destruction.  The unused study 
drug can only be destroyed after being inspected and reconciled by [CONTACT_1034]’s study monitor.    
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102684] s in a secure location for a minimum period of 2 years after 
licensure for marketing of drug or 15 years from the close of the trial or until receipt of 
notification by [CONTACT_799416]. 
 Protocol Deviations 
The Investigator is not  permitted to alter or deviate from the protocol without a written waiver 
from the Sponsor.  This waiver shou ld also be reported by [CONTACT_799417]/her 
IRB/IEC/REB.  An immediate and un approved deviation is permitte d if immediate subject safety 
concerns mandate a deviation. 
 Study Termination 
The Sponsor may terminate the study at any time.  If the study is terminated, the Sponsor will promptly notify the Investigator to enter no further subjects o n the study and remove current 
subjects from the study.  The Sponsor will also inform regulato ry authorities of the action. 
1. The study will also be termin ated when the objectives have b een fully met and all of the 
designated data collected. 
2. The Sponsor reserves the right  to terminate an Investigator’s participation in this clinical 
trial for refusal of the Investigator and/or site to comply with any requirements stated in this clinical protocol. 
 Use of Data and Publication 
All data and results and intell ectual property rights in the da ta and results that are derived from 
the study will be property of CPP.  CPP may utilize the results and data in variety of ways including submission to regulator y authorities or to other inve stigators under disclosure.  Data 
from any individual center must not be published or presented u ntil the complete multicenter 
study has been published or presented in full.  Subsequently, a n investigator may use the data 
derived from the clinical study for scientific purposes but mus t discuss any publication with the 
Sponsor prior to submission or  release of any data.  The Sponso r is aware of the rights of an 
Investigator to publish the resu lts when the study is completed , and the Investigator must provide 
a draft of the abstract or manuscript to the Sponsor within [ADDRESS_1102685] or manuscript.  The Sponsor will provide a timely review and response to the Investigator.  In the event of a  difference of opi[INVESTIGATOR_799330], all 
efforts will be put forth to find a solution that is agreeable to both the Sponsor and Investigator.  
However, the final decision fo r submission/dissemination of res ults rests solely with the 
Investigator. 
   
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102686] been fully reviewed 
and approved by [CONTACT_40291]’s IRB/IEC/REB.  The approval and associated documents will be provided to the Sponsor.  All relevant regula tions of the regulatory authorities 
will be followed. 
 Ethical Conduct 
The study will be conducted in compliance with the regulations from the FDA, Health Canada, 
local competent authorities, and the EMA, including Protection of Human Volunteers (21 CFR 
50), Institutional Review Board s (21 CFR 56), Good Clinical Practice guidelines (ICH), and 
Obligations of Clinical Investig ators (21 CFR 312), Food and Dr ug Regulations (C.R.C., C.870), 
C.05.001 - Division 5, Drugs For Clinical Trials Involving Human Subjects, Regulation (EU) No.1235/2010, Directive 2010/84/EU, Directive 2001/20/EC (The C linical Trials Directive), 
Commission Directive 2005/28/EC ( The GCP Directive), and any ot her applicable country 
specific regulations. 
The protocol will be reviewed and approved by [CONTACT_1356]’ s IRB/IEC/REB, and as 
applicable, any country or regional IRB/IEC/REB.  Written docum entation of the IRB/IEC/REB 
approval of the protocol and informed consent must be provided by [CONTACT_799418].  Serious adverse events regardless of causality will be reported 
to the Sponsor and to the IRB/IEC/REB, and the Investigator wil l keep the IRB/IEC/REB 
informed as to the progress of the study. 
 Informed Consent 
The Investigator or his designee will explain the nature of the study and will inform the subject 
that participation is voluntary and that they can withdraw at a ny time.  Written informed consent 
and required authorization to use private information will be obtained and documented from each subject prior to entry into the study. 
The consent form generated by [CONTACT_3433] e Investigator must be approved  by [CONTACT_1201]/IEC/REB and be 
acceptable to Cancer Prevention Pharmaceuticals.  Each subject’ s signed informed consent form 
must be kept on file by [CONTACT_799419] n by [CONTACT_799420]. 
 Confidentiality 
The Investigator and his staff shall maintain the confidentiali ty of all subject records.  Subject 
data will be made available upon request to monitors from CPP C orporation (study Sponsor), 
regulatory authorities, the Ins titutional Review Board, Independent Ethics Committee, or 
Research Ethics Board, and to other government agencies that ha ve responsibility for clinical 
research activities. 
Data that is released by [CONTACT_67852], regulatory authorities, or the 
IRB/IEC/REB will not be directly traceable to the subject.  In the event that a publication of this 
research incorporates a subject’s medical data, the data will not identify the subject. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102687] Aspartate Amino Transferase
BID Twice a da y 
0C Degrees centi grade
CBC Complete blood cell coun t
CFR Code Federal Re gulations
CIOMS Council for International Or ganizations of Medical Sciences
cm Centimeters 
COX Cycloox ygenase 
CPP Cancer Prevention Pharmaceuticals
CPP-1X Eflornithine, DFMO, difluorometh ylorthine
CRC colorectal cance r 
CRF Case report form 
CTCAE Common Terminolo gy Criteria for Adverse Events
dB Decibels 
DFMO Eflornithine, CPP-1X, difluorometh ylorthine
dL decilite r 
DMC Data Monitorin g Committee
DMSO Dimeth ylsulfoxide
DNA Deox yribonucleic Aci d
EDTA Ethylene Diamine Tetra Acetic Aci d
EFS Event free survival
EKG Electrocardio gram
EORTC European Or ganization for Research a nd Treatment of Cance r
EOT End of Treatmen t
EU Europe 
FAP Familial Adenomatous pol yposis
FDA Food and Dru g Administration
FFQ Food Frequenc y Questionnaire
GCP Good Clinical Practices
GI Gastrointestinal 
HCG Human Chorionic Gonadotropin
HDPE High densit y polyethlylene
HEENT Head, Ear, E yes, Nose, Throa t
HGD High grade d ysplasia
HRQoL Health-Related Qualit y of Life
IB Investi gator’s Brochure
ICH International Committee on Harmonization
IME Important medical even t
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  71 Abbreviation Description 
IND Investi gational New Dru g Application
InSiGHT International Societ y for Gastrointestinal Hereditar y Tumours
IRA Ileal-rectal anastomosis
IRB/IEC/REB Institutional Review Board/Independent Ethics Commi ttee/Research Ethics Boar d
ITT Inten t-to trea t 
IUD, IUS Intrauterine device, Intrauterine s ystem
LGI Lower gastrointestinal
LGIOI LGI Observed Improvemen t
LOCF Last observation carried forwar d
mg milli grams 
mL milliliters 
mm millimeters 
MST Mountain Standard Time
N Normal 
NCBI National Center for Biotechnolo gy information
NCI National Cancer Institute
NSAIDS Nonsteroidal anti-inflammator y drugs
NASR Nutrition Assessment Shared Resource
ODC Ornithine decarbox ylase
OMIM Online Mendelian Inheritance in Man
PCR Polymerase Chain Reaction
PK Pharmacokinetics
PO By [CONTACT_1966], orall y 
PSA Prostate specific anti gen
QLQ  Qualit y of Life Questionnaire 
QoL  Qualit y of Life  
RNA Ribonucleic acid 
RSI Reference Safet y Information
RX Treatmen t 
SAE Serious Adverse Even t
SAP Statistical Anal ysis Plan
SNP Single nucleotide polymorphis m
Spd:Sp m Spermidine to spermine ratio
SWOG Southwest Oncolo gy Group
TEN Toxic epi[INVESTIGATOR_799331] t
ULN Upper limit of normal
US [LOCATION_002] 
T1/2 Half-life 
WBC White Blood Cell
WHO World Health Or ganization
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  72 16. REFERENCES 
 1. Spi[INVESTIGATOR_702987], Williams CB, Talbot IC, et al: Upper gastroin testinal cancer in 
patients with familial adenomat ous polyposis. Lancet:783-785, 1989 
 2. Bulow S, Bjork J, Christense n IJ, et al: Duodenal adenomato sis in familial 
adenomatous polyposis. Gut 53:381-6, 2004 
 3. Wu JS, McGannon EA, Church JM: Incidence of neoplastic poly ps in the ileal 
pouch of patients with familial ad enomatous polyposis after res torative proctocolectomy. Dis 
Colon Rectum 41:552-6;  discussion 556-7, 1998 
 4. Tekkis PP, Fazio VW, Lavery I C, et al: Evaluation of the le arning curve in ileal 
pouch-anal anastomosis s urgery. Ann Surg 241:262-8, 2005 
 5. Tajika M, Nakamura T, Nakahara O, et al: Prevalence of aden omas and 
carcinomas in the ileal pouch after proctocolectomy in patients  with familial adenomatous 
polyposis. J Gastrointest Surg 13:1266-73, 2009  6. Groves CJ, Beveridge l G, Swa in DJ, et al: Prevalence and morphology of pouch 
and ileal adenomas in familial adenomatous  polyposis. Dis Colon Rectum 48:816-23, 2005 
 7. Sturt NJ, Clark SK: Current i deas in desmoid tumours. Fam C ancer 5:275-85; 
discussion 287-8, 2006  8. Sinha A, Tekkis PP, Neale KF, et al: Risk factors predictin g intra-abdominal 
desmoids in familial adenomatous  polyposis: a single centre exp erience. Tech Coloproctol 
14:141-6, 2010  9. Church J, Lynch C, Neary P, et al: A desmoid tumor-staging system separates 
patients with intra-abdominal, familial adenomatous polyposis-a ssociated desmoid disease by 
[CONTACT_799421]. Dis Colon Rectum 51:897-901, 2008 
 10. Vasen HF, Moslein G, Alonso A , et al: Guidelines for the c linical management of 
familial adenomatous pol yposis (FAP). Gut 57:704-13, [ADDRESS_1102688], Ready RL, et al: Treatment of small colorectal 
polyps: a population-based study of  the risk of subsequent carc inoma. Mayo Clin Proc 59:305-
10, 1984  12. Lotfi AM, Spencer RJ, Ilstrup DM, et al: Colorectal polyps  and the risk of 
subsequent carcinoma. Mayo Clin Proc 61:337-43, 1986  13. Atkin WS, Morson BC, Cuzick J: Long-term risk of colorecta l cancer after 
excision of rectosigmoid adenomas. N Engl J Med 326:658-62, 199 2 
 14. Winawer SJ, Zauber AG, Ho MN, et al: The National Polyp Study. Eur J Cancer Prev [ADDRESS_1102689] 2:83-7, 1993  15. Martinez ME, Baron JA, Lieberman DA, et al: A pooled analysis of advanced colorectal neoplasia diagnoses  after colonoscopic polypectomy. Gastroenterology 136:832-41, 
2009  16. Wallace MH, Lynch PM: The current status of chemopreventio n in FAP. Fam 
Cancer 5:289-94; discussion 295-6, 2006  17. Labayle D, Fischer D, Vielh P, et al: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635-9, 1991 
 18. Nugent KP, Farmer KC, Spi[INVESTIGATOR_702987], et al: Randomized cont rolled trial of the 
effect of sulindac on duodenal a nd rectal polyposis and cell pr oliferation in patie nts with familial 
adenomatous polyposis. Br J Surg 80:1618-9, 1993  19. Giardiello FM, Hamilton SR, Krush AJ, et al: Treatment of colonic and rectal 
adenomas with sulindac in famil ial adenomatous polyposis. N Engl J Med 328:1313-6, 1993 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  73  20. Tonelli F, Valanzano R, Messerini L, et al: Long-term trea tment with sulindac in 
familial adenomatous polyposis: is  there an actual efficacy in prevention of rectal cancer? J Surg 
Oncol 74:15-20, 2000 
 21. Cruz-Correa M, Hylind LM, R omans KE, et al: Long-term trea tment with 
sulindac in familial adenomatous polyposis: a prospective cohor t study. Gastroenterology 
122:641-5, 2002  22. Giardiello FM, Yang VW, Hylind LM, et al: Primary chemopre vention of familial 
adenomatous polyposis with su lindac. N Engl J Med 346:1054-9, 2 002 
 23. Bertagnolli MM, Eagle CJ, Zauber AG, et al: Celecoxib for the prevention of sporadic colorectal adenoma s. N Engl J Med 355:873-84, 2006 
 24. Arber N, Eagle CJ, Spi[INVESTIGATOR_702989] J, et al: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-95, 2006  25. Steinbach G, Lynch PM, Phillips RK, et al: The effect of c elecoxib, a 
cyclooxygenase-2 inhibitor, in f amilial adenomatous polyposis. N Engl J Med 342:1946-52, 
2000  26. Phillips RK, Wallace MH, Lynch PM, et al: A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inh ibitor, on duodenal polyposis in 
familial adenomatous p olyposis. Gut 50:857-60, 2002 
 27. Lynch PM, Rodriguez-Bigas M , Burke CA, et al: An Internati onal, Randomized 
Trial of Celecoxib Plus Difluorom ethylornithine in Patients wit h Familial Adenomatous 
Polyposis. Gastrointestinal Endoscopy 75:AB285, 2012  28. Lynch PM, Burke CA, Phillip s R, et al: An international ra ndomised trial of 
celecoxib versus celecoxib plus difl uoromethylornithine in pati ents with familial adenomatous 
polyposis. Gut 65:286-95, 2016  29. Erdman SH, Ignatenko NA, Powell MB, et al: APC-dependent c hanges in 
expression of genes influenci ng polyamine metabolism, and conse quences for gastrointestinal 
carcinogenesis, in the Min mous e. Carcinogenesis 20:1709-13, 19 99 
 30. Yerushalmi HF, Besselsen DG, Ignatenko NA, et al: Role of polyamines in 
arginine-dependent colon carcinoge nesis in Apc(Min) (/+) mice. Mol Carcinog 45:764-73, 2006 
 31. Ignatenko NA, Besselsen DG, Stringer DE, et al: Combination chemoprevention of intestinal carcinogenesis in a  murine model of familial aden omatous polyposis. Nutr Cancer 
[ADDRESS_1102690] 1:30-5, 2008  32. Simoneau AR, Gerner EW, Nagle R, et al: The effect of difl uoromethylornithine 
on decreasing prostate size and pol yamines in men: results of a  year-long phase IIb randomized 
placebo-controlled chemoprevention trial. Cancer Epi[INVESTIGATOR_799332] 17:292-9, 2008 
 33. Bailey HH, Kim K, Verma AK, et al: A randomized, double-bl ind, placebo-
controlled phase 3 skin cancer prevention study of {alpha}-difl uoromethylornithine in subjects 
with previous history of skin cancer. Cancer Prev Res (Phila) 3:35-47, 2010  34. McLaren CE, Fujikawa-Brooks S, Chen WP, et al: Longitudina l assessment of air 
conduction audiograms in a phase I II clinical trial of difluoro methylornithine and sulindac for 
prevention of sporadic colorecta l adenomas. Cancer Prev Res (Ph ila) 1:514-21, 2008 
 35. Meyskens FL, Jr., Gerner EW, Emerson S, et al: Effect of a lpha-
difluoromethylornith ine on rectal mucosal levels of polyamines in a randomized, double-blinded 
trial for colon cancer preven tion. J Natl Cancer Inst 90:1212-8 , 1998 
 36. Martinez ME, O'Brien TG, Fultz KE, et al: Pronounced reduc tion in adenoma 
recurrence associated with aspi[INVESTIGATOR_799333] a polymorphism in th e ornithine decarboxy
lase gene. 
Proc Natl Acad Sci U S A 100:7859-64, 2003 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  74  37. Hubner RA, Muir KR, Liu JF , et al: Ornith ine decarboxylase G316A genotype is 
prognostic for colorectal adenoma recurrence an d predicts effic acy of aspi[INVESTIGATOR_799334]. 
Clin Cancer Res 14:2303-9, 2008 
 38. Brown I, Halliday S, Greig H, et al: Genetic polymorphism in ornithine 
decarboxylase and risk of breast cancer. Fam Cancer 8:307-11, 2 009 
 39. Visvanathan K, Helzlsouer KJ, Boorman DW, et al: Associati on among an 
ornithine decarboxylase polymorphism, androgen receptor gene (C AG) repeat length and 
prostate cancer ris k. J Urol 171:652-5, 2004 
 40. Zell JA, Ziogas A, Ignatenko N , et al: Associations of a polymorphism in the 
ornithine decarboxylase gene with colorectal cancer survival. C lin Cancer Res 15:6208-16, 2009 
 41. Meyskens FL, Jr., McLaren C E, Pelot D, et al: Difluorometh ylornithine plus 
sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, 
double-blind trial. Cancer Prev Res (Phila) 1:32-8, 2008  42. Gerner EW, Meyskens FL, Jr.: Polyamines and cancer: old mo lecules, new 
understanding. Nat Rev Cancer 4:781-92, 2004  43. Gerner EW, Meyskens FL, Jr. : Combination chemoprevention f or colon cancer 
targeting polyamine synthesis a nd inflammation. Clin Cancer Res  15:758-61, 2009 
 44. Giardiello FM, Hamilton SR, Hylind LM, et al: Ornithine decarboxylase and polyamines in familial adenom atous polyposis. Cancer Res 57:199 -201, 1997 
 45. Meyskens FL, Jr., Gerner EW : Development of difluoromethyl ornithine (DFMO) 
as a chemoprevention agent. Clin Cancer Res 5:945-51, 1999  46. Babbar N, Ignatenko NA, Cas ero RA, Jr., et al: Cyclooxygenase-independent 
induction of apoptosis by [CONTACT_799422] c sulfone is mediated by [CONTACT_799423]. J Biol 
Chem 278:[ZIP_CODE]-75, 2003  47. Pendyala L, Creaven PJ, Porte r CW: Urinary and erythrocyte polyamines during 
the evaluation of oral alpha-difl uoromethylornithine in a phase  I chemoprevention clinical trial. 
Cancer Epi[INVESTIGATOR_1948] 2:235-41, 1993  48. Mamont PS, Duchesne MC, Grove J, et al: Anti-proliferative  properties of DL-
alpha-difluoromethyl ornithine i n cultured cells. A consequence  of the irreversi ble inhibition of 
ornithine decarboxylase. Bioch em Biophys Res Commun 81:58-66, 1978 
 49. Reagan-Shaw S, Nihal M, Ahm ad N: Dose translation from animal to human 
studies revisited. FASEB J 22:659-61, 2008  50. Thompson PA, Wertheim BC, Zell JA, et al: Levels of rectal  mucosal polyamines 
and prostaglandin E2 predict abil ity of DFMO and sulindac to pr event colorectal adenoma. 
Gastroenterology 139:797-805, 805 e1, 2010  51. Hixson LJ, Garewal HS, McGee DL, et al: Ornithine decarbox ylase and 
polyamines in colorectal neoplas ia and mucosa. Cancer Epi[INVESTIGATOR_1948] 2:369-74, 
1993  52. Lawson KR, Ignatenko NA, Pi[INVESTIGATOR_799335], et al: Influence of K- ras activation on the 
survival responses of Caco-2 cells  to the chemopreventive agent s sulindac and 
difluoromethylornithine. Cancer Epi[INVESTIGATOR_1948] 9:1155-62, 2000 
 53. Davies NM, Watson MS: Clini cal pharmacokinetics of sulinda c. A dynamic old 
drug. Clin Pharmacokinet 32:437-59, 1997  54. Keller JJ, Offerhaus GJ, Giardiello FM, et al: Jan Peutz, Harold Jeghers and a 
remarkable combination of polyposis and pi[INVESTIGATOR_799336]. Fam Cancer 1:181-5, 2001 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  75  55. Winde G, Gumbinger HG, Osswald H, et al: The NSAID sulinda c reverses rectal 
adenomas in colectomized patient s with familial adenomatous pol yposis: clinical results of a 
dose-finding study on rectal sulin dac administration. Int J Col orectal Dis 8:13-7, 1993 
 56. Spagnesi MT, Tonelli F, Dolara P, et al: Rectal proliferation and polyp occurrence 
in patients with familial adenom atous polyposis a fter sulindac treatment. Gastroenterology 
106:362-6, 1994  57. Iwama T, Imajo M, Mishima Y: Is sulindac effective for fam ilial adenomatous 
polyposis? Int J Colorectal Dis 6:235, 1991  58. Ishikawa H, Akedo I, Suzuki T, et al: Adverse effects of s ulindac used for 
prevention of colorectal cancer . J Natl Cancer Inst 89:1381, 1997 
 59. Lynch PM: Pharmacotherapy for  inherited colorectal cancer.  Expert Opin 
Pharmacother 11:1101-8, 2010  60. Solomon SD, Pfeffer MA, McMurray JJ, et al: Effect of cele coxib on 
cardiovascular events and blood pressure in two t rials for the prevention of colorectal adenomas. 
Circulation 114:1028-35, 2006  61. Zell JA, Pelot D, Chen WP, et al: Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithi ne plus sulindac for the prevention 
of sporadic colorectal adenomas . Cancer Prev Res (Phila) 2:209- 12, [ADDRESS_1102691] T, Kim K, et al: A Phase III Skin Can cer Chemoprevention 
Study of DFMO: Long-term Follow-up of Skin Cancer Events and To xicity. Cancer Prev Res 
(Phila) 5:1368-74, 2012  63. Chaturvedi R, Jha CB: Standa rd manufacturing procedure of Rajata Bhasma. Ayu 
32:566-71, 2011  64. FDA strengthens warning tha t non-aspi[INVESTIGATOR_799337] 
(NSAIDs) can cause heart attacks or strokes, FDA Drug Safety Co mmunications, 2015 
 65. Brosens LA, Keller JJ, Offerhaus GJ, et al: Prevention and  management of 
duodenal polyps in familial ad enomatous polyposis. Gut 54:1034-43, 2005 
 66. Sener SF, Miller HH, DeCosse JJ: The spectrum of polyposis. Surg Gynecol Obstet 159:525-32, 1984  67. Trivedi CD, Pi[INVESTIGATOR_293754]: Drug-induced pancreatitis: an u pdate. J Clin 
Gastroenterol 39:709-16, 2005  68. Hixson LJ, Emerson SS, Shassetz LR, et al: Sources of vari ability in estimating 
ornithine decarboxylas e activity and polyami ne contents in human colorectal mucosa. Cancer 
Epi[INVESTIGATOR_1948] 3:317-23, 1994  69. Zoumas-Morse C, Rock CL, Qui ntana EL, et al: Development o f a polyamine 
database for assessing dietary in take. J Am Diet Assoc 107:1024-7, 2007 
 70. Aaronson NK, Ahmedzai S, Bergm an B, et al: The European Or ganization for 
Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J  Natl Cancer Inst 85:365-76, 1993 
 71. Whistance RN, Conroy T, Chi e W, et al: Clinical and psychometric validation of 
the EORTC QLQ-CR29 questionnai re module to assess health-relate d quality of life in patients 
with colorectal cancer. Eur J Cancer 45:3017-26, 2009  72. Brooks R: EuroQol: the curre nt state of play. Health Polic y 37:53-72, 1996 
 73. Drummond MF, O’Brien B, Stoddart GL, et al: Methods for th e Economic 
Evaluation of Health Care Programme (ed 2nd). [LOCATION_001], Oxford University Press, 1997  
 74. Lerman C, Trock B, Rimer BK, et al: Psychological side effects of breast cancer screening. Health Psychol 10:259-67, 1991 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  76  75. Lopez-Garcia C, Lopez-Contre ras AJ, Cremades A, et al: Mol ecular and 
morphological changes in placenta and embryo development associ ated with the inhibition of 
polyamine synthesis during midpr egnancy in mice. Endocrinology 149:5012-23, 2008 
 76. Abeloff MD, Slavik M, Luk GD, et al: Phase I trial and pharmacokinetic studies 
of alpha-difluoromethylornithine- -an inhibitor of polyamine biosynthesis. J Clin Oncol 2:124-30, 
1984  77. Haegele KD, Alken RG, Grove J, et al: Kinetics of alpha-di fluoromethylornithine: 
an irreversible inhibitor of or nithine decarboxylase. Clin Pharmacol Ther 30:210-7, 1981 
 78. Balmana J, Balaguer F, Cerva ntes A, et al: Familial risk-colorectal cancer: ESMO 
Clinical Practice Guidelin es. Ann Oncol [ADDRESS_1102692] 6:vi73-80, 2013 
 79. Kahwati LC, Haigler L, Rideout S, et al: What is the best way to diagnose 
menopause? J Fam Pract 54:1000-2, 2005  80. Pagana KD PT: Mosby's Manua l of Diagnostic and Laboratory Tests (ed 4th ed.). 
St. Louis, Mosby [CONTACT_54469], 2010   81. Church J, Berk T, Boman BM, et al: Staging intra-abdominal  desmoid tumors in 
familial adenomatous polyposis: a search for a uniform approach  to a troubling disease. Dis 
Colon Rectum 48:1528-34, 2005  82. Kristal AR, Shattuck AL, Williams AE: Food frequency quest ionnaires for diet 
intervention research, 17th Nati onal Nutrient Databank Conferen ce. Baltimore, MD, 1992, pp 
110-125  83. Neuhouser ML, Kristal AR, M cLerran D, et al: Validity of s hort food frequency 
questionnaires used in cancer che moprevention trials: results f rom the Prostate Cancer 
Prevention Trial. Cancer Epi[INVESTIGATOR_650351] 8:721-5, 199 9 
 84. Raj KP, Zell JA, Rock CL, e t al: Role of dietary polyamines in a phase III clinical 
trial of difluoromethylornithin e (DFMO) and sulindac for prevention of sporadic colorectal 
adenomas. Br J Cancer 108:512-8, [ADDRESS_1102693]: Regression models and life tables. J Royal Stat Soc Series B:[ZIP_CODE]-[ZIP_CODE], 1972  86. Kaplan E, Meier P: Nonparame tric estimation from incomplete observations. J. 
Amer. Stat. Assoc. 53:457-481, 1958  87. Freedman LS: Tables of the num ber of patients required in clinical trials using the 
logrank test. Stat Med 1:121-9, 1982  88. Schoenfeld D: The asymptoti c properties of nonparametric t ests for comparing 
survival distributions. Biometrika 68:316-319, 1981  89. Lehmann EL: Nonparametrics:  statistical methods based on r anks. San Francisco, 
Holden-Day, 1975   90. Schulz KF, Altman DG, Moher D, et al: CONSORT 2010 stateme nt: updated 
guidelines for reporting parallel  group randomise d trials. PLoS  Med 7:e1000251, 2010 
 91. Fleiss J, Levin B, Paik MC: S tatistical Methods for Rates and Proportions (ed 3rd 
Edition), [LOCATION_001]: John Wiley & Sons.  See generally Section 2 .7.1 and especially Section 
10.3 at page 243., 2003   92. Saurin JC, Gutknecht C, Napoleon B, et al: Surveillance of  duodenal adenomas in 
familial adenomatous polyposis r eveals high cumulative risk of advanced disease. J Clin Oncol 
22:493-8, 2004  93. Schlemper RJ, Riddell RH, Kato Y, et al: The Vienna classification of gastrointestinal epi[INVESTIGATOR_372277]. Gut 47:251-5, 2000 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  77  94. Lynch PM, Morris JS, Wen S, et al: A proposed staging system and stage-specific 
interventions for familial ade nomatous polyposis. Gastrointest Endosc 84:115-125 e4, 2016 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  78 APPENDIX A SPI[INVESTIGATOR_799285]’S SCORE AND STAGE _ENREF_92  
Modified Spi[INVESTIGATOR_350126]’s Score and Classification (Saurin, 2004)92 
 Score 
Factor 1 Point 2 Points 3 Points 
No. of polyps 1-4 5-20 > 20 
Polyp size, mm 1-4 5-10 > 10 
Histology Tubulous Tubulovillous Villous 
Dysplasia Low grade — High grade* 
NOTE:  Classification as follows based on score scale. 
Stage 0:  no polyps 
Stage 1:  1 to 4 points 
Stage 2:  5 to 6 points 
Stage 3:  7 to 8 points 
Stage 4:  9 to 12 points 
*High-grade dysplasia would be a ssigned to any epi[INVESTIGATOR_799338]. It c an encompass intraepi[INVESTIGATOR_799339] a rchitecture but still all located above 
the basement membrane. 
Comment: All adenomas in the duodenum demonstrate at least low grade dysplasia; if intermediate 
grade use low gr ade for points. 
Vienna Classification of Gastroi ntestinal Epi[INVESTIGATOR_33962] (Schlemper et al.,  2000)93 
Category 1 Ne gative for neoplasia/d ysplasi a
Category 2 Indefinite for neoplasia/d ysplasi a
Category 3 Non-invasive low grade neoplasia (low grade adenoma/d ysplasia) 
Category 4 Non-invasive  high grade neoplasia 
4.1 High grade adenoma/dysplasia 
4.2 Non-invasive carcinoma (carcinoma in situ)a 
4.3 Suspi[INVESTIGATOR_799340] a
Category 5 Invasive neoplasia 
5.1 Intramucosal carcinomab 
5.2 Submucosal carcinoma or be yond
a Non-invasive indicated ab sence of evident invasion. 
b Intramucosal indicated invasion into the lamina  propria or muscularis mucosae. 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  79 APPENDIX B InSiGHT RECTUM/POUCH ASSESSM ENT AND STAGE94 
 
_ENREF_95  
 
Patients who cannot be allotted a  particular stage (e.g., patie nts with mix pol yposis) contact 
[CONTACT_799424] a ssignment. Stage Polyp Description Recommended 
Intervention Comment 
0 0-10 polyps, all <5mm Repeat FS in [ADDRESS_1102694] <5mm, none >1cm Ablate polyps; repeat 
sigmoidoscopy in 1 year Chemopreventive may be considered 
2 10-25 polyps, any >1cm, amenable to complete removal  Repeat sigmoidoscopy 6 months 
Polypectomy preferred Removal of large 
polyps clearly necessary 
Chemopreventive 
valuable 
3 > 25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any prior evidence of HGD, even if completely excised Repeat sigmoidoscopy 3-6 months; consider proctectomy Large polyps must be removed; second opi[INVESTIGATOR_799341] 
4 >25 polyps not amenable to complete removal, or any incompletely excised sessile polyp showing HGD; any invasive cancer Proctectomy/pouch revision +/- ileostomy clearly indicated within [ADDRESS_1102695] be highly individualized and based on compelling circumstances 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-[ADDRESS_1102696] course of therapy, physicians of ten assess the stage  of heart failure 
according to the [LOCATION_001] Heart Association (NYHA) functional classification system.  This 
system relates symptoms to eve ryday activities and the patient' s quality of life. 
Class  Patient Symptoms  
Class I (Mild) No limitation of physical activity. Ordinary phy sical activity does 
not cause undue fatigue, palpit ation, or dyspnea (shortness of 
breath). 
Class II (Mild) Slight limita tion of physical ac tivity. Comfort able at rest, but 
ordinary physical activity res ults in fatigue, palpi[INVESTIGATOR_332], or 
dyspnea. 
Class III (Moderate) Marked li mitation of physical activity. Co mfortable at rest, but 
less than ordinary activity causes fatigue, palpi[INVESTIGATOR_332], or dys pnea. 
Class IV (Severe) Unable to carry out any physical activity wit hout discomfort. 
Symptoms of cardiac insufficiency  at rest. If any physical acti vity 
is undertaken, discomfort is increased. 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  81 APPENDIX D Desmoid Staging System9 
 
Stage Description 
I Asymptomatic, <10 cm m aximum diameter, and not 
growin g* 
II Mildly symptomatic, <10 cm maximum diameter, and not 
growin g 
III Moderately symptomatic or bow el/ureteric obstruction, or 10  
to 20 cm, or slowl y growin g
IV Severely symptomatic, or  >20 cm, or rapi[INVESTIGATOR_799342] = sensation of mass, pain, but no restrictions;  
Moderately symptomatic = sensatio n of mass, pain; restrictive but not hospi[INVESTIGATOR_057];  
Severely symptomatic = sensation of mass, pain; restrictive and  hospi[INVESTIGATOR_057]. 
* Stage I may also include larger, stable, asymptomatic desmoid s 
 
_ENREF_95  
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  82 APPENDIX E Event Rate Summary Table 
Familial Adenomatous Polyposis ( FAP) Review:  Evidence-Based Projected Event Rates at 2 Years 
Rectum (after IRA) and Pouch (a fter Ileal-Pouch Anal Reconstruc tion)
Key References  Comments Event/Rate
Bertagnolli, et al., N Eng J Med, [ADDRESS_1102697], et al., Gut, 2010 
 
 • 80% of patients develop ade nomas within the pouch body. 
• 71% ↓of adenomas after 4-6 mo. Sulindac (300-400mg/day)-
analysis combined randomized studies. 
• Incidence of pouch adenomas is time-dependent with 42% of patients at 7 yrs from pouch construction. 
• Median time from pouch construction to diagnosis pouch adenomas, 4.7 yrs (0.5-12 yrs). 
• Celecoxib treated patients, med ian time to first polypectomy 
post IRA was 18.69 months; 90.9% (30 patients) had a post IRA rectal polypectomy. 
• Celecoxib treated patients, pos t IPAA, 3 of 24 pts (12.5%) had 
post IPAA polypectomy, [ADDRESS_1102698] polypectomy in  IPAA patients was 169.9 months • 80% of patients develop ade nomas within the pouch body. 
• Celecoxib treated patients, med ian time to first polypectomy po st IRA was 18.69 
months; 90.9% (30 patients) had a post IRA rectal polypectomy. 
 
 
 
Duodenal Disease 
Key References  Comments Event/Rate
• Recurrence rate of adenoma development is > 
50% after endoscopic treatment and treatment is associated with 17% complication rate (perforation, hemo rrhage, pancreatitis) 
• Rate of progression between Spi[INVESTIGATOR_799343], 4 – 11 yrs  • 95-100% of all FAP patients develop duodenal adenomas 
• 10-25% of patients have Stage III/IV 
• 36% of Spi[INVESTIGATOR_799344] g IV develop cancer 
• Endoscopic resection/ablation - local recurrence rate 72.5% wit h 
mean follow-up interval of 12.8 months.  Surgical resection-
30% mean follow-up of  44 months, Definitiv e resection 47 pts 
with recurrence rate of 9%.  Surgical morbidity-48%. 
• Patients down staged from Spig elman stage IV demonstrate 
increased rate of disease progression back to severe disease. 
Pre-Colectomy 
 Comments Event/Rate
 • Diagnosis with recommendation to proceed with prophylactic 
colectomy or proctocolectomy. 
 
 Summary Projected 2 year Event Rate: Excisional 
intervention and/or high risk adenoma – 40-60% 
Summary Projected 2 Year Event Rate: Excisional 
intervention, cancer – 90% Summary Projected 2 Year Event Rate: Excisional 
intervention, cancer – 50% 